

1 EXP1 is required for organization of the intraerythrocytic malaria parasite vacuole

2

3 Timothy Nessel^a, John M. Beck^a, Shima Rayatpisheh^b, Yasaman Jami-Alahmadi^b, James A.

4 Wohlschlegel^b, Daniel E. Goldberg^{c,d}, Josh R. Beck^{a,c,d}#

5

6

7

8 ^aDepartment of Biomedical Sciences, Iowa State University, Ames, Iowa, USA

9 ^bDepartment of Biological Chemistry, University of California, Los Angeles, California, USA.

10 ^cDivision of Infectious Diseases, Department of Medicine, Washington University, St. Louis,

11 Missouri, USA

12 ^dDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis,

13 Missouri, USA

14

15

16 Running title: Functional analysis of *Plasmodium falciparum* EXP1

17

18

19 #Address correspondence to Josh R. Beck, jrbeck@iastate.edu.

20

21

22 Abstract word count: 250

23

24

25 Importance word count: 149

26

27 **Abstract**

28 Intraerythrocytic malaria parasites reside within a parasitophorous vacuole membrane (PVM)
29 that closely overlays the parasite plasma membrane (PPM) and constitutes the barrier between
30 parasite and host compartments. The PVM is the site of several essential transport activities but
31 the basis for organization of this membrane system is unknown. We utilized the second-
32 generation promiscuous biotin ligase BioID2 fused to EXP2 or HSP101 to probe the content of
33 the PVM, identifying known and novel candidate PVM proteins. Among the best represented
34 hits were members of a group of single-pass integral membrane proteins that constitute a major
35 component of the PVM proteome but whose function remains unclear. We investigated the
36 function of EXP1, the longest known member of this group, by adapting a CRISPR/Cpf1
37 genome editing system to install the TetR-DOZI-aptamers system for conditional translational
38 control. EXP1 knockdown was essential for intraerythrocytic development and accompanied by
39 profound changes in vacuole ultrastructure, including increased separation of the PVM and
40 PPM and formation of abnormal membrane structures in the enlarged vacuole lumen. While
41 previous *in vitro* studies indicated EXP1 possesses glutathione S-transferase activity, a mutant
42 version of EXP1 lacking a residue important for this activity *in vitro* still provides substantial
43 rescue of endogenous *exp1* knockdown *in vivo*. Intriguingly, while activity of the *Plasmodium*
44 translocon of exported proteins was not impacted by depletion of EXP1, the distribution of the
45 translocon pore-forming protein EXP2 was substantially altered. Collectively, our results reveal
46 a novel PVM defect that indicates a critical role for EXP1 in maintaining proper PVM
47 organization.

48

49 **Importance**

50 Like other obligate intracellular apicomplexans, blood-stage malaria parasites reside within a
51 membrane-bound compartment inside the erythrocyte known as the parasitophorous vacuole.
52 Although the vacuole is the site of several transport activities essential to parasite survival, little

53 is known about its organization. To explore vacuole biology, we adopted recently developed
54 proteomic (BioID2) and genetic (CRISPR/Cpf1) tools for use in *Plasmodium falciparum*, which
55 allowed us to query the function of the prototypical vacuole membrane protein EXP1.
56 Knockdown of EXP1 showed that a previously reported glutathione S-transferase activity cannot
57 fully account for the essential function(s) of EXP1 and revealed a novel role for this protein in
58 maintaining normal vacuole morphology and PVM protein arrangement. Our results provide new
59 insight into vacuole organization and illustrate the power of BioID2 and Cpf1 (which utilizes a T-
60 rich PAM uniquely suited to the *P. falciparum* genome) for proximity protein identification and
61 genome editing in *P. falciparum*.

62

63 **Introduction**

64 The obligate intracellular malaria parasite *Plasmodium falciparum* resides within a
65 parasitophorous vacuole (PV) established during host cell invasion which constitutes the
66 principal barrier between the parasite and its host cell (1). During the parasite blood stage,
67 several essential transport activities at this membrane enable host erythrocyte subversion and
68 parasite growth (2). This includes the uptake of large amounts of host cytosol through a process
69 involving a double-membrane invagination of the parasitophorous vacuole membrane (PVM)
70 and parasite plasma membrane (PPM) known as the cytostome (3). Catabolism of hemoglobin,
71 the principal component of this ingested material, provides free amino acids for parasite
72 metabolism and opens space within the host compartment for parasite expansion (4-6). The
73 vacuole is also a key trafficking site for the export of hundreds of parasite proteins which are
74 first secreted into the PV and then translocated across the PVM by the *Plasmodium* translocon
75 of exported proteins (PTEX) (7-9). The PTEX core complex is composed of the HSP101 AAA+
76 ATPase chaperone, which unfolds exported cargo and passes it through an oligomeric pore in
77 the PVM formed by a second PTEX protein, EXP2 (10). A third component, PTEX150, serves to
78 couple HSP101 to the pore. While proteins must be unfolded to pass through the EXP2 pore

79 (11), small molecules up to 1,400 Da can pass through this channel, allowing for nutrient uptake
80 and waste exchange (12-14).

81 Aside from EXP2, the known *P. falciparum* PVM proteome is comprised mainly of a
82 group of single-pass integral membrane proteins oriented with C-terminus facing the host
83 cytosol and N-terminus in the PV lumen (15-17). This group consists of the prototypical PVM
84 protein EXP1 and the early transcribed membrane proteins (ETRAMPs, also known as small
85 exported proteins (SEPs) in *P. berghei*) and contains some of the most highly expressed genes
86 in the blood stage (17-19). The function of these proteins is largely unknown although EXP1 has
87 been shown to possess glutathione S-transferase (GST) *in vitro*, which has been proposed to
88 support detoxification of heme released by hemoglobin catabolism (20).

89 One of the most striking features of the PV is the intimate proximity of the PVM and
90 PPM, which is maintained until a very late stage of parasite development when PVM rounding
91 occurs just prior to egress (2, 21). Additional lateral organization of this compartment is
92 suggested by the formation of distinct oligomeric arrays of EXP1 and ETRAMPs in the PVM (22)
93 and by the non-uniform distribution of PTEX components as well as PV-targeted exported and
94 non-exported fluorescent fusion reporter proteins, which have been shown to display a punctate
95 distribution in the PV described as a “necklace of beads” (7, 23-27). Visualized by
96 immunofluorescence, this punctate arrangement is most prominent in the early ring stage of
97 parasite development and resolves into a more homogenous distribution in the trophozoite and
98 schizont stage, particularly for EXP2 (26). While these observations point to a highly
99 coordinated membrane system, the basis for PV/PVM organization is unknown.

100 Here, we applied the second generation BioID2 proximity ligase system fused to multiple
101 components of PTEX to probe the protein content of the PV and PVM, revealing known vacuole
102 proteins as well as novel PV/PVM candidates. To interrogate the function of select hits, we
103 adapted a CRISPR/Cpf1 system that recognizes a T-rich protospacer adjustment motif, greatly
104 expanding the repertoire of guide RNA targets available for editing the *P. falciparum* genome.

105 Prompted by the high representation of EXP1 in our BioID2 datasets, we used Cpf1 editing to
106 generate an EXP1 conditional knockdown mutant to explore its function. Depletion of EXP1
107 produced a lethal defect that was largely rescued by a mutant version of EXP1 shown to be
108 defective in GST activity *in vitro*, suggesting that this activity does not fully account for EXP1
109 function *in vivo*. Instead, EXP1 knockdown resulted in dramatic changes to PV morphology and
110 PVM protein organization, revealing a novel role in maintaining proper order within the PV.

111

112 **Materials and Methods**

113

114 **Parasite Culture**

115 Deidentified, IRB-exempt red blood cells (RBCs) were obtained from the American National Red
116 Cross. *P. falciparum* NF54^{attB} and derivatives were maintained under 5% O₂, 5% CO₂, and 90%
117 N₂ at 2% hematocrit in RPMI 1640 supplemented with 27 mM sodium bicarbonate, 11 mM
118 glucose, 0.37 mM hypoxanthine, 10 µg/ml gentamicin and 0.5% Albumax I (Gibco).

119

120 **Plasmids and genetic modification of *P. falciparum***

121 Cloning was carried out with Infusion (Clontech) or NEBuilder HiFi (NEB) unless noted
122 otherwise. Primer and synthetic gene sequences are given in Table S1. To generate a BioID2
123 fusion to the endogenous EXP2 C-terminus, the coding sequence of the *Aquifex aeolicus* biotin
124 ligase with an R40G mutation (BioID2) bearing a 3' 3xHA epitope tag was amplified with primers
125 P1/P2 from plasmid MCS-BioID2-HA (28) (Addgene #74224) and inserted between AvrII and
126 EagI in plasmid pyPM2GT-EXP2-mNeonGreen (29), replacing the AvrII site with an NheI site
127 and resulting in the plasmid pyPM2GT-EXP2-BioID2-3xHA. This plasmid was linearized at the
128 AflIII site between the 3' and 5' homology flanks and co-transfected with pUF-Cas9-EXP2-CT-
129 gRNA (14) into NF54^{attB}. Selection was applied with 2 µM DSM1 (30) 24 hours post-transfection.

130 A clonal line was isolated by limiting dilution after parasites returned from selection and
131 designated NF54^{attB}::EXP2-BioID2-3xHA.

132 For fusion of BioID2 to endogenous HSP101, a flank assembly targeting the 3' end of
133 *hsp101* was amplified from plasmid pPM2GT-HSP101-3xFlag (14) with primers P3/P4 and
134 inserted between XhoI and NheI in pyPM2GT-EXP2-BioID2-3xHA, resulting in plasmid
135 pyPM2GT-HSP101-BioID2-3xHA. This plasmid was linearized at AflII, co-transfected with
136 plasmid pAIO-HSP101-CT-gRNA (14) into NF54^{attB}, selected with 2 μ M DSM1 and cloned upon
137 returning from selection, resulting in the line NF54^{attB}::HSP101-BioID2-3xHA.

138 For Cas9-mediated editing of the *exp1* locus, the pAIO (31) plasmid was first simplified
139 by removing the yDHODH-2A fusion to Cas9-NLS-FLAG using a QuikChange Lightning Multi
140 Site Directed Mutagenesis kit (Agilent) and the primer P5, resulting in the plasmid pAIO2. The
141 BtgZI site in the pre-sgRNA cassette was then replaced with AflII by inserting the annealed
142 sense and antisense oligo pair P6/P7 into BtgZI, resulting in the plasmid pAIO3. Three Cas9
143 targets were chosen at the 3' end of *exp1* (GACGACAACAACCTCGTAAG,
144 AGGTTGTTGTCGTCACCTTG and AGTGTTTCAGTGCCACTTACG) and each guide RNA
145 (gRNA) seed sequence was synthesized as a sense and anti-sense oligo pair (P8/P9, P10/P11,
146 and P12/P13, respectively). Each oligo pair was annealed and inserted into the AflII site of
147 pAIO3 to yield the plasmids pAIO3-EXP1-CT-gRNA1, pAIO3-EXP1-CT-gRNA2 and pAIO3-
148 EXP1-CT-gRNA3.

149 For Cpf1 editing, AsCpf1 and LbCpf1 were PCR amplified from plasmids pcDNA3.1-
150 hAsCfp1 and pcDNA3.1-hLbCfp1 (Addgene #69982 and #69988) (32) with primer pairs P14/15
151 and P16/15, respectively, and inserted into pAIO3 between BamHI and XhoI. The Cas9 pre-
152 gRNA cassette was then replaced with a pre-gRNA cassette with the appropriate direct repeat
153 region for AsCpf1 or LbCpf1 using a QuikChange Lightning Multi Site Directed Mutagenesis kit
154 and the primers P17 or P18, resulting in plasmids pAIO-AsCpf1 and pAIO-LbCpf1, respectively.
155 For Cpf1-mediated editing of the *exp1* locus, two Cpf1 targets were chosen at the 3' end of *exp1*

156 (CAGCTGTTTAGTGTTTCAGTGCCAC and GTGTTTCAGTGCCACTTACGAGGTT) and each
157 gRNA seed sequence was synthesized as a sense and anti-sense oligo pair for AsCpf1
158 (P19/P20 and P21/P22, respectively) and LbCpf1 (P23/P24 and P25/P26, respectively). Each
159 oligo pair was annealed and inserted into the AflII site of pAIO-AsCpf1 or pAIO-LbCpf1 to yield
160 the plasmids pAIO-AsCpf1-EXP1-CT-gRNA1, pAIO-AsCpf1-EXP1-CT-gRNA2, pAIO-LbCpf1-
161 EXP1-CT-gRNA1 and pAIO-LbCpf1-EXP1-CT-gRNA2. To generate selectable Cpf1 plasmids,
162 the AflII site between the yDHODH and Cas9 expression cassettes in the plasmid pUF-Cas9-
163 pre-sgRNA (14) was replaced with an XmaI site using QuikChange Lightning Multi Site Directed
164 Mutagenesis kit and the primer P27. The Cpf1 coding sequence with the PbDT 3' UTR and
165 adjacent pre-gRNA cassette was then amplified from pAIO-AsCpf1 or pAIO-LbCpf1 using
166 primers P28/P29 or P28/P30 and inserted between XhoI and NotI, resulting in the plasmids
167 pUF-AsCpf1-pre-gRNA and pUF-LbCpf1-pre-gRNA, respectively. Oligo pairs P21/P22 and
168 P25/P26 were annealed and inserted into the AflII site in the pre-gRNA cassette of these
169 vectors to yield pUF-AsCpf1-EXP1-CT-gRNA2 and pUF-LbCpf1-EXP1-CT-gRNA2, respectively.

170 For fusion of 3xHA-GFP11 to EXP1, a 5' homology flank (up to, but not including, the
171 stop codon) was amplified from NF54^{attB} genomic DNA using the primers P31/P32. As the *exp1*
172 coding sequence did not allow for synonymous mutations in the protospacer adjustment motifs
173 of the three Cas9 gRNAs, several synonymous mutations were incorporated in the seed
174 sequences of these target sites. A 3' homology flank (beginning 11 bp downstream of the stop
175 codon) was amplified using the primers P33/P34 and the flank amplicons were assembled in a
176 second PCR reactions using the primers P32/P33 and inserted between XhoI and AvrII in
177 pyPM2GT-EXP2-3xHA-GFP11 (14), resulting in the plasmid pyPM2GT-EXP1-3xHA-GFP11.
178 This plasmid was linearized at the AflII site between the 3' and 5' homology flanks and co-
179 transfected into NF54^{attB} with the above Cas9 and Cpf1 plasmids designed to target *exp1*.
180 Selection was applied with DSM1 and the expected integration was confirmed by diagnostic
181 PCR using primers P35/P36.

182 For generation of the ETRAMP10.2^{apt} and ETRAMP5^{apt} lines bearing a 3xHA fusion, a
183 Cpf1 gRNA target was chosen just upstream of the *etramp10.2* and *etramp5* stop codons
184 (TGACTCTTGGTGTGGTACTTCTTC and GGTTCTTCGGTTTTGACTTCGTCT, respectively)
185 and the gRNA seed sequences were synthesized as the sense and anti-sense primer pairs
186 P37/P38 and P39/P40, which were annealed and inserted into the AflII site of the plasmid pAIO-
187 AsCpf1, resulting in the plasmids pAIO-AsCpf1-ETRAPM10.2-gRNA1 and pAIO-AsCpf1-
188 ETRAMP5-gRNA1. A modified version of the plasmid pMG75 (33) was generated by first
189 replacing the AvrII site with an NcoI site using a QuikChange Lightning Multi Site Directed
190 Mutagenesis kit and the primer P41. The BirA*-3xHA coding sequence from plasmid pBirA*-
191 3xHA-LIC-DHFR (34) was then amplified with primers P42/P43 and inserted between
192 BstEII/AatII and the *2xattP* sequence was subsequently removed by using QuikChange
193 Lightning Multi Site Directed Mutagenesis kit and the primer P44, resulting in the plasmid
194 pMG75 Δ attP-BirA*-3xHA. To target the 3' end of *etramp10.2* or *etramp5*, a 5' homology flank
195 (up to but not including the stop codon) was amplified from NF54^{attB} genomic DNA using primers
196 pairs P45/P46 or P47/P48, incorporating synonymous mutations in the seed sequence and
197 protospacer adjustment motif of the gRNA target sites within each *etramp* coding sequence. A
198 3' homology flank (beginning 89 or 257 bp downstream of the stop codon, respectively) was
199 amplified using the primer pairs P49/P50 or P51/P52. The corresponding 5' and 3' flank
200 amplicons were assembled in a second PCR reaction using the primer pairs P46/P49 and
201 P48/P51 and inserted between AscI/AvrII in pMG75 Δ attP-BirA*-3xHA, removing the BirA*
202 sequence and resulting in the plasmids pMG75 Δ attP-ETRAPM10.2-3xHA and pMG75 Δ attP-
203 ETRAMP5-3xHA. These plasmids were linearized at the AflII site and co-transfected with the
204 corresponding pAsCpf1-gRNA plasmid into NF54^{attB} parasites. Cultures were maintained with
205 1 μ M aTc from the time of transfection and selection with 2.5 μ g/ml Blasticidin-S was applied 24
206 hours post-transfection. After returning from selection, parasites were cloned and proper

207 integration at the 3' end of *etramp10.2* or *etramp5* was confirmed by PCR with primer pairs
208 P53/P36 or P54/P36, respectively.

209 For generation of a combined TetR-DOZI-aptamers (TDA) and DiCre knockdown system
210 to target *exp1*, the tandem NLS-FKBP12-Cre19-59 and NLS-FRB-Cre60-343 cassettes from
211 plasmid pDiCre (35) were amplified with primers P55/P56 and inserted into the *Ascl* site of
212 plasmid pSN054 (36), a pJAZZ-based plasmid containing the TDA elements. This plasmid also
213 contains *loxP* sites immediately upstream of the 5' aptamer and immediately downstream of the
214 TetR-DOZI cassette. The latter *loxP* site is adjacent to the *Ascl* site and was removed during
215 insertion of the DiCre cassette. To target *exp1*, 5' and 3' homology flanks immediately upstream
216 and downstream of the *exp1* start and stop codons were amplified with the primer pairs
217 P57/P58 and P59/P60 and inserted sequentially at *FseI* (5' flank) and between *I-CeuI*/*I-SceI* (3'
218 flank). A promoterless *mruby3* coding sequence with the *hsp86* 3' UTR was amplified from
219 plasmid pLN-HSP101-SP-mRuby3 (21) using primers P61/P62, adding a *loxP* site immediately
220 before the *mruby3* start codon, and inserted at *I-CeuI*. Finally, the *exp1* coding sequence
221 (without introns) was recoded, synthesized as a gene block (IDT) and PCR amplified with
222 primers P63/P64, adding a 3' 3xHA tag, and inserted at *AsiSI*, resulting in the plasmid pEXP1^{apt}.
223 This plasmid was co-transfected with pAIO-LbCpf1-EXP1-CT-gRNA1 into NF54^{attB}::HSP101-
224 3xFLAG (14). Parasites were maintained with 1 μM aTc from the time of transfection and 2.5
225 μg/ml Blasticidin-S was applied 24 hours later. A clonal line was isolated by limiting dilution after
226 parasites returned from selection and designated EXP1^{apt}. Integration at the 5' and 3' ends of
227 the *exp1* locus was evaluated by PCR with primer pairs P65/P36 and P66/P67, respectively.
228 Excision by DiCre was monitored with the primers P65/P68.

229 For complementation of EXP1^{apt} parasites, the re-coded *exp1* coding sequence (without
230 introns) was PCR amplified from the synthesized gene block with primers P69/P70 and inserted
231 between *XhoI* and *NheI* in pyEOE-attP-EXP2-3xMYC (14), resulting in the plasmid pyEOE-attP-
232 EXP1-WT-3xMYC. The *exp1* codon 70 in this plasmid was then changed from AGA to ACA

233 using a QuikChange Lightning Multi Site Directed Mutagenesis kit and the primer P71, resulting
234 in the plasmid pyEOE-attP-EXP1-R70T-3xMYC. Finally, the mNeonGreen coding sequence
235 was amplified from pyPM2GT-EXP2-mNeonGreen (29) with primers P72/P73 and inserted at
236 NheI in pyEOE-attP-EXP1-WT-3xMYC, resulting in the plasmid pyEOE-attP-EXP1-
237 mNeonGreen-3xMYC. Complementing plasmids were co-transfected with pINT (37) into
238 EXP1^{apt} parasites to facilitate integration into the *attB* site on chromosome 6 and selection with
239 2 μ M DSM1 was applied 24 hours post-transfection (in addition to 2.5 μ g/ml Blasticidin-S and
240 1 μ M aTc for maintenance of endogenous *exp1* control by the TetR-DOZI-aptamers system).
241 Parasites were cloned when they returned from selection and expression of EXP1 second
242 copies was confirmed by Western blot.

243 For targeting mRuby3 to the PV, the *exp2* promoter and signal peptide were amplified
244 from NF54^{attB} genomic DNA with primers P74/P75 and inserted between AatII and NheI in
245 plasmid pyEOE-attP-EXP2-3xMYC (14), replacing the *hsp86* promoter and *exp2* coding
246 sequence. The mRuby3 coding sequence was then PCR amplified from pLN-HSP101-SP-
247 mRuby3 (21) using primers P76/P77 and inserted between NheI and EagI, replacing the 3xMYC
248 sequence and resulting in the plasmid pyEOE-attP-EXP2-5'UTR-SP-mRuby3. This plasmid was
249 co-transfected with pINT (37) into EXP1^{apt} parasites, selection was applied 24 hours post-
250 transfection with 2 μ M DSM1 and parasites were cloned upon returning from selection.

251 To monitor EXP2 by live fluorescence in EXP1^{apt}, an endogenous mNeonGreen fusion to
252 EXP2 was generated by co-transfecting EXP1^{apt} with plasmids pyPM2GT-EXP2-mNeonGreen
253 (29) (linearized at AflIII) and pUF-Cas9-EXP2-CT-gRNA (14). Selection was applied 24 hours
254 post-transfection with 2 μ M DSM1 and parasites were cloned upon returning from selection.

255

256 **Proximity labeling and mass spectrometry**

257 Parasites were synchronized to an ~8 hour window by treatment with 5% w/v D-sorbitol and 200
258 μ M exogenous biotin was added in the ring stage. After 18 hours, trophozoite and schizont-

259 infected RBCs were purified on an LD column mounted on a QuadroMACs magnetic separator
260 (Miltenyi Biotech), washed in PBS to remove residual biotin and lysed in RIPA buffer containing
261 protease inhibitors. Lysates were briefly sonicated and insoluble material and hemozoin was
262 cleared by centrifugation before loading onto streptavidin magnetic beads (Pierce). After rotating
263 at 4°C overnight, beads were washed 5X with RIPA followed by 5X washes in 50 mM Tris 6.8
264 containing 8M urea.

265 Protein samples were reduced and alkylated using 5mM Tris (2-carboxyethyl) phosphine
266 and 10mM iodoacetamide, respectively, and then enzymatically digested by the sequential
267 addition of trypsin and lys-C proteases as described (38, 39). The digested peptides were
268 desalted using Pierce C18 tips (Thermo Fisher Scientific), dried and resuspended in 5% formic
269 acid. Approximately 1 µg of digested peptides were loaded onto a 25 cm long, 75 µm inner
270 diameter fused silica capillary packed in-house with bulk C18 reversed phase resin (1.9 µm, 100A
271 pores, Dr. Maisch GmbH). The 140-minute water-acetonitrile gradient was delivered using a
272 Dionex Ultimate 3000 UHPLC system (Thermo Fisher Scientific) at a flow rate of 200 nl/min
273 (Buffer A: water with 3% DMSO and 0.1% formic acid and Buffer B: acetonitrile with 3% DMSO
274 and 0.1% formic acid). Eluted peptides were subsequently ionized by the application of a distal
275 2.2kv and introduced into the Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher
276 Scientific) and analyzed by tandem mass spectrometry (MS/MS). Data was acquired using a
277 Data-Dependent Acquisition (DDA) method consisting of a full MS1 scan (Resolution = 120,000)
278 followed by sequential MS2 scans (Resolution = 15,000) to utilize the remainder of the 3 second
279 cycle time.

280 Data analysis was accomplished using the Integrated Proteomics pipeline 2 (Integrated
281 Proteomics Applications, San Diego, CA). Data was searched against the protein database from
282 *Plasmodium falciparum* 3D7 downloaded from UniprotKB (10,826 entries) on October 2013.
283 MS/MS spectra searched using the ProLuCID algorithm followed by filtering of peptide-to-

284 spectrum matches (PSMs) by DTASelect using a decoy database-estimated false discovery rate
285 of <1%.

286

287 **Antibodies**

288 The following antibodies were used for immunofluorescence assays (IFA) and western blot
289 (WB) analysis at the indicated dilutions: mouse anti-HA monoclonal antibody HA.11 (Covance;
290 1:500 WB); rabbit polyclonal anti-HA SG77 (ThermoFisher; 1:500 IFA and WB); mouse anti-
291 Flag monoclonal antibody clone M2 (Sigma; 1:300 IFA); mouse anti-EXP1 monoclonal antibody
292 (20) (1:500 WB); mouse anti-EXP2 monoclonal antibody clone 7.7 (40) (1:500 IFA and WB);
293 rabbit polyclonal anti-SBP1 (41) (1:500 IFA); mouse anti-cMYC monoclonal antibody 9E10
294 (ThermoFisher; 1:166 IFA and WB); rabbit polyclonal anti-*Plasmodium* Aldolase ab207494
295 (Abcam; 1:500 WB).

296

297 **Western blot**

298 Western blots were carried out as previously described (14) and imaging with an Odyssey
299 infrared imaging system (Li-COR Biosciences). Biotinylated proteins were detected with IRDye
300 800-conjugated streptavidin used at 1:200. Signal quantification was performed with Image
301 Studio software (Li-COR Biosciences).

302

303 **Parasite growth assays**

304 Parasite cultures were washed five times to remove aTc, then plated at 5% parasitemia
305 (percentage of total RBCs infected) with or without 1 μ M aTc in triplicate. Every 24 hours, media
306 was changed and parasitemia was measured by flow cytometry on an Attune NxT
307 (ThermoFisher) by nucleic-acid staining with PBS containing 0.8 μ g/ml acridine orange.
308 Subculture (1:1) was performed each day parasitemia exceeded 10% and half as often for -aTc
309 cultures within that group containing parasitemia less than 1%. Cumulative parasitemia was

310 back-calculated based on subculture schedule, data were log₂ transformed and fitted to a linear
311 equation to determine slope using Prism (Graphpad).

312

313 **Transmission electron microscopy**

314 EXP1^{apt} parasites were extensively washed to remove aTc, replated and allowed to develop 48
315 hours with or without aTc along with the parental NF54^{attB}:HSP101-3xFLAG line. Trophozoite-
316 and schizont-infected RBCs were purified on an LD column mounted on a QuadroMACs
317 magnetic separator and fixed in 100 mM sodium cacodylate buffer, pH 7.2 containing 2%
318 paraformaldehyde and 2.5% glutaraldehyde (Polysciences) for 1 hour at room temperature for
319 ultrastructural analyses. Samples were washed in sodium cacodylate buffer at room
320 temperature and post-fixed in 1% osmium tetroxide (Polysciences) for 1 hour. Samples were
321 then extensively rinsed in dH₂O before en bloc staining with 1% aqueous uranyl acetate (Ted
322 Pella) for 1 h. Following several rinses in water, samples were dehydrated in a graded series of
323 ethanol and embedded in Eponate 12 resin (Ted Pella). Sections (95 nm thick) were cut with a
324 Leica Ultracut UCT ultramicrotome (Leica Microsystems), stained with uranyl acetate and lead
325 citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA)
326 equipped with an AMT 8-megapixel digital camera and AMT Image Capture Engine V602
327 software (Advanced Microscopy Techniques). For quantification of abnormalities, 100
328 trophozoites and 100 segmented schizonts were scored in each of two independent replicates.

329

330 **Immunofluorescence imaging**

331 For IFAs, cells were fixed with a mixture of cold 90% acetone and 10% methanol for 2 minutes,
332 except for export assays where fixation was carried out with room temperature 100% acetone
333 for 2 minutes, and processed as described (9). For detection of biotinylated proteins,
334 streptavidin-conjugated Alexa Fluor 594 (ThermoFisher) was included with secondary
335 antibodies at 1:200. Images were collected on an Axio Observer 7 equipped with an AxioCam

336 702 mono camera and Zen 2.6 Pro software (Zeiss) using the same exposure times for all
337 images across sample groups and experimental replicates.

338

339 **Quantification of protein export**

340 IFA analysis of protein export was performed as described (14) except that image quantification
341 was carried out using the Image Analysis module in Zen 2.6 Pro (Zeiss). The border of each
342 single-infected RBC was traced using the DIC channel as a reference and the PVM was marked
343 using the “Segment by Global Thresholding” tool for the HSP101-3xFLAG-488 channel (low and
344 high thresholds set at 600 and 16,383 respectively and the Fill Holes option enabled). The
345 signal corresponding to exported SBP1 was determined by removing any SBP1 signal within the
346 PVM from the total SBP1 signal in each cell. Individual Maurer’s clefts were identified using the
347 “Dynamic Thresholding” tool for the SBP1-594 channel (smoothing set to 7, threshold set to -
348 500, minimum area set to 10 and the Watersheds option enabled with count set to 1) and
349 removing puncta within the PVM boundary from the total SBP1 puncta within each cell.

350

351 **Live-fluorescent imaging of EXP2-mNeonGreen distribution**

352 Parasite cultures were washed 5 times to remove aTc, then plated with or without 1 μ M aTc and
353 cultured for 48 hours. Trophozoite and schizont-infected RBCs were magnet purified and
354 stained with 2.5 μ M BODIPY TR Ceramide (Thermo Fisher) for 15 minutes at 37°C, washed
355 once with media and immediately imaged. For each replicate, 40 single-infected RBCs were
356 selected moving top to bottom and left to right in each field to avoid bias. For each infected
357 RBC, the circumference of the PVM was traced with the profile tool in Zen 2.6 Pro using the
358 BODIPY TR Ceramide signal at the parasite periphery as a guide with the green channel turned
359 off to blind the experimenter to the mNeonGreen (mNG) signal. The mNG fluorescent intensity
360 along each PVM trace was then collected, mNG signal and distance along the trace were
361 normalized and data were analyzed with custom R scripts (ver. 3.5.2). In one approach, peaks

362 were designated as mNG fluorescent intensity that exceeded the mean of the minimum and
363 maximum intensity for at least 3 measured points before falling below this threshold. In an
364 alternative approach, minimum PVM circumference containing indicated amounts of EXP2-mNG
365 fluorescent signal was determined as the shortest distance along the PVM trace that returned
366 the designated portion of total fluorescent signal throughout the trace. Means from three
367 independent experiments were fitted to a smooth line with JMP Pro (ver. 14.2.0).

368

369 **Live-fluorescent imaging of PV-mRuby3**

370 Parasite cultures were washed 5 times to remove aTc, then plated with or without 1 μ M aTc and
371 cultured for 48 hours. Trophozoite and schizont-infected RBCs were magnet purified and
372 stained with 1 μ g/ml Hoechst 33342 trihydrochloride trihydrate (ThermoFisher) for 15 min at
373 37°C, washed once with media and immediately imaged.

374

375 **Data Availability**

376 Custom R scripts used in this study are available at <https://github.com/tnessel/Beck-Lab>

377

378 **Results**

379

380 **Identification of proteins at the luminal face of the PVM with BioID2**

381 To probe the protein content of the PV/PVM, we attempted to fuse the BioID proximity
382 labeling system to the endogenous EXP2 protein. However, repeated attempts to generate an
383 EXP2-BioID fusion with a verified CRISPR/Cas9 strategy for editing the 3' end of *exp2* were
384 unsuccessful. Endogenous EXP2 can tolerate a monomeric NeonGreen (mNG, 27 kDa) fusion
385 without an obvious fitness cost (29); thus the bulkier size (35 kDa) or enzymatic activity of BioID
386 may interfere with EXP2 trafficking or essential functions. To test the former possibility, we next

387 attempted fusion with the second generation BioID2 derived from *Aquifex aeolicus* (Figure 1A).
388 BioID2 lacks the DNA-binding domain present in the *E. coli*-derived BioID, resulting in a smaller
389 size (27 kDa) that has been shown to reduce trafficking defects relative to BioID fusions (28).
390 Parasites with an endogenous EXP2-BioID2 fusion were easily obtained and displayed robust
391 biotinylation activity at the PVM (Figure S1A and Figure 1B), suggesting the additional ~9 kDa
392 BioID DNA-binding domain is not compatible with EXP2 function. As an additional probe, we
393 also generated parasites with an endogenous HSP101-BioID2 fusion (Figure 1A,B). As EXP2
394 appears to be expressed at a stoichiometrically higher level than HSP101 and a fraction of
395 PTEX-independent EXP2 exists (14, 24, 26), we reasoned that these two fusions would similarly
396 position BioID2 within PTEX proximal to the luminal face of the PVM but might allow distinct
397 proximity labeling by the PTEX-independent fraction of EXP2 that could provide clues to its dual
398 function or organization in the PVM.

399 Western blot of EXP2-BioID2 and HSP101-BioID2 lysates showed extensive protein
400 biotinylation relative to parental controls and supplementation of cultures with 200 μ M
401 exogenous biotin for 18 hours produced an approximately 2-fold increase in streptavidin signal
402 over parallel cultures maintained in standard RPMI containing 820 nM biotin (Figure 1C).
403 Overall biotinylation levels were higher in EXP2-BioID2 lines which may reflect the higher level
404 of EXP2 expression relative to HSP101 (14). Although streptavidin-labeled banding patterns
405 were distinct between the EXP2-BioID2 and HSP101-BioID2 lysates, both lines showed several
406 strongly labeled bands migrating at molecular weights consistent with other PTEX components
407 (Figure 1C, arrowheads). As expected, the most strongly labeled band in each lysate
408 corresponded with the BioID2-3xHA fusion. Notably, a band migrating at ~23 kDa displayed
409 prominent labeling in both lines (Figure 1C, arrow).

410 To identify labeled proteins, synchronized parasite cultures were supplemented with 200
411 μ M biotin in the ring stage and allowed to develop for 18 hours. Parasite-infected RBCs were
412 magnetically purified before lysis, streptavidin chromatography and subsequent analysis by

413 mass spectrometry to identify biotinylated proteins. Mass spectrometry datasets from two
414 independent experiments performed with EXP2-BioID2 or HSP101-BioID2 identified ~10-fold
415 more proteins than untagged parental controls and were substantially overlapping and highly
416 enriched for known PV/PVM proteins (Figure 1D and Table S2). The highest-ranking proteins by
417 normalized spectral abundance factor (NSAF) identified in both EXP2-BioID2 and HSP101-
418 BioID2 included protein export machinery (PTEX and EPIC (42) complexes) and other proteins
419 known to reside in the PV lumen, exported proteins and the PVM membrane proteins EXP1 and
420 ETRAMP10.2 (Table 1). Beyond the top ~10% of each dataset, many additional known PV/PVM
421 and exported proteins were identified (Table S2).

422 EXP1 and ETRAMP10.2, both single-pass PVM membrane proteins with similar
423 expression timing to EXP2 (Figure S1B), ranked particularly high across all BioID2 experiments.
424 When Western blots of lysates from EXP2-BioID2 and HSP101-BioID2 were probed with an
425 anti-EXP1 monoclonal antibody, the signal coincided with the prominent ~23 kDa band labeled
426 by streptavidin (EXP1 is known to migrate at 23 kDa, higher than its predicated molecular
427 weight of 14.7 kDa following signal peptide cleavage (43)), consistent with the high level of
428 EXP1 representation in the BioID2 proteomics (Figure 1E). ETRAMP5, another member of this
429 group, was also well represented (though not consistently among the top hits). The functions of
430 ETRAMP10.2, ETRAMP5 and EXP1 are not known. Given their high level of representation
431 implying particular abundance and/or an intimate proximity to EXP2/PTEX, we focused on
432 functional characterization of these three proteins.

433

434 **Efficient genome editing in *P. falciparum* with Cpf1/Cas12a**

435 CRISPR/Cas9 genome editing technology has been rapidly adapted for manipulation of
436 *P. falciparum*. A limitation of Cas9-mediated editing is the requirement for a “GG” in the
437 protospacer adjacent motif (PAM), as such sites are comparatively rare given the high A+T
438 content of the *P. falciparum* genome (80.6%) (44). The type II, class V CRISPR endonuclease

439 Cpf1 (CRISPR from *Prevotella* and *Francisella*, also known as Cas12a) has recently emerged
440 as a favorable alternative to Cas9 with an inherently lower level of off-target cleavage (45, 46).
441 In contrast to Cas9, Cpf1 does not require a trans activating CRISPR (tracr) RNA, introduces a
442 staggered double-strand break in target DNA that is distal from the PAM and utilizes a T-rich
443 PAM, making it uniquely suited to editing the *P. falciparum* genome (32).

444 Cpf1 from *Acidaminococcus* sp. BV3L6 and *Lachnospiraceae* bacterium ND2006
445 (AsCpf1 and LbCpf1, respectively) have been shown to mediate efficient genome editing in
446 mammalian cells (32) and we tested both of these enzymes for their genome editing capacity in
447 *P. falciparum* relative to a Cas9 editing system we previously developed (14, 31). The 3' region
448 of *exp1* was found to contain attractive Cas9 and Cpf1 target sites located in close proximity,
449 providing an opportunity for initial Cpf1 testing (Figure 2A). We generated plasmids for
450 expression of AsCpf1 or LbCpf1 and corresponding gRNAs to target two sites with Cpf1 near
451 the *exp1* stop codon. In parallel, we generated constructs for targeting partially overlapping or
452 immediately adjacent sites with Cas9 (Figure 2A). These markerless Cas9 and Cpf1 editing
453 plasmids were co-transfected with a donor plasmid bearing a yDHODH cassette and flanks
454 designed to repair the intended double-strand breaks by double homologous recombination to
455 introduce a 3xHA-GFP11 tag at the 3' end of *exp1* (Figure 2A). In each case, parasites returned
456 from DSM1 selection in about 21 days with the expected edit, as gauged by diagnostic PCR and
457 Western blot (Figure 2B). To provide a tool for marker-free editing, we additionally generated
458 AsCpf1 and LbCpf1 vectors with a yDHODH cassette to allow for selection in parasites and
459 showed that these vectors also facilitated editing of the *exp1* locus (Figure S2A).

460 Encouraged by these results, we next applied the AsCpf1 system to edit the *etramp10.2*
461 and *etramp5* loci to insert a 3xHA-epitope and simultaneously install the TetR-DOZI-aptamers
462 (TDA) system for conditional translational repression (Figure S2B-D) (31, 33). Editing of the 3'
463 end of both loci was also successful (Figure S2C,D), however both ETRAMP10.2^{apt} and
464 ETRAMP5^{apt} parasite lines were found to have truncated 3' aptamer arrays (reduced from 10X

465 to 6X, data not shown). Partial truncation of 3' aptamers rapidly diminishes translational control
466 (31) and anhydrotetracycline (aTc) washout did not result in measurable knockdown (Figure
467 S2C,D), thus ETRAMP10.2 and ETRAMP5 were not pursued further in this study. Collectively,
468 these results indicate Cpf1 editing of the *P. falciparum* genome is equally efficient to Cas9 with
469 Cpf1 offering many additional gRNA targets owing to its T-rich PAM requirement.

470

471 **Lethal EXP1 knockdown with a dual aptamer strategy**

472 To query EXP1 function in PV biology, we employed a dual aptamer TDA strategy using
473 a linear plasmid system to replace the endogenous *exp1* coding sequence in an NF54^{attB}
474 parasite line bearing a 3xFLAG tag on the endogenous *hsp101* gene (10, 14). This was
475 accomplished by LbCpf1 editing to introduce an aptamer just upstream of the start codon and a
476 10X aptamer array just downstream of the stop codon (Figure 3A and Figure S3A,B).

477 Installation of 5' aptamers has been shown to reduced baseline expression even in the
478 presence of aTc (14) and the resulting EXP1^{apt} parasites showed 87.5±7.2% reduction in EXP1
479 expression and a growth defect relative to the parent line (Figure 3B,C). Removal of aTc further
480 reduced EXP1 levels (99.3±0.4% knockdown relative to parent by probing with anti-EXP1 and
481 65.9±3.1% relative to EXP1^{apt} +aTc by probing with anti-HA) and resulted in a complete block in
482 parasite growth, indicating EXP1 is required for intraerythrocytic development (Figure 3B,C).

483 As a complement to the titratable translational control afforded by the TDA system and
484 to simultaneously provide a parallel option for conditional knockout, we also engineered the
485 donor plasmid to place *loxP* sites around the recoded *exp1* gene and inserted cassettes for
486 expression of the rapamycin-inducible dimerizable Cre recombinase (DiCre) downstream of the
487 modified *exp1* locus (Figure S3A). Treatment of EXP1^{apt} cultures with rapamycin induced the
488 expected excision event as gauged by diagnostic PCR but produced only modest impact on
489 parasite growth (Figure S2C-E). Consistent with this, the non-excised locus remained readily

490 detectable in these cultures even when parasites were grown for several days with rapamycin,
491 indicating inefficient excision of *exp1* that was unsuitable for functional analysis (Figure S2E).
492 The reason for the poor excision efficiency by DiCre in EXP1^{apt} was not explored further and the
493 robust translational knockdown achieved by TDA was used for the remainder of the study.

494

495 **EXP1 functional constraints**

496 While a 3xHA-GFP11 tag (6.2 kDa) could be efficiently fused to the endogenous EXP1
497 C-terminus (Figure 2), multiple attempts using the same editing strategy failed to generate an
498 endogenous fusion to mNG or BioID2, suggesting the essential function of EXP1 is perturbed by
499 bulky C-terminal fusions (data not shown). To directly test this possibility, we complemented the
500 EXP1^{apt} parasites with a second copy of EXP1 bearing either a 3xMYC (4.5 kDa) or mNG-
501 3xMYC (31.5 kDa) fusion (Figure 4A). While both versions of EXP1 were similar expressed,
502 only the 3xMYC fusion was able to rescue parasite growth upon aTc removal (percent growth
503 rate in -aTc relative to +aTc control was $7.28 \pm 20\%$ in mNG-3xMYC compared with $67.63 \pm 7.36\%$
504 in WT-3xMYC and $7.76 \pm 2.14\%$ in uncomplemented EXP1^{apt}), indicating that introduction of a
505 bulky C-terminal fusion does indeed ablate EXP1 function (Figure 4B,C). Similar to EXP1-
506 3xMYC, EXP1-mNG-3xMYC still localized at the parasite periphery with endogenous EXP1-
507 3xHA but tended to show a more dispersed distribution possibly indicating perturbations in
508 trafficking (Figure 4D).

509 EXP1 has previously been reported to possess GST activity based on an *in silico*
510 functional prediction approach and *in vitro* biochemical analysis (20). This study identified the
511 arginine at position 70 in EXP1 as critical for GST activity *in vitro* and our functional
512 complementation system provided the opportunity to test the importance of this residue *in vivo*
513 by complementing EXP1^{apt} parasites with an EXP1-R70T-3xMYC mutant (Figure 4A,B). Similar
514 to the wild-type second copy, EXP1-R70T-3xMYC colocalized with endogenous EXP1-3xHA at

515 the PVM (Figure 4D). To our surprise, the R70T mutant also provided substantial rescue upon
516 knockdown of endogenous EXP1 (percent growth rate in -aTc relative to +aTc control was
517 $46.21 \pm 6.05\%$ in R70T-3xMYC compared with $67.63 \pm 7.36\%$ in WT-3xMYC), suggesting that
518 GST activity cannot fully explain the *in vivo* function of EXP1 (Figure 4C).

519

520 **Depletion of EXP1 results in late cycle arrest and PV/PVM morphological abnormalities**

521 While EXP1 expression peaks about midway through the intraerythrocytic development
522 cycle (Figure S1B), EXP1 has been localized to merozoite dense granules and is thus expected
523 to be delivered to the PVM immediately following RBC invasion and accumulate to peak levels
524 later in the cycle (47). To determine the impact of EXP1 knockdown on parasite development
525 from the point of invasion on, trophozoites (~32-42 hours post invasion) were magnet-purified
526 from synchronized cultures, washed of aTc to prevent new synthesis of EXP1 during dense
527 granule formation at the terminal stages of schizogony and used to initiate cultures with fresh
528 uninfected RBCs. New ring formation was not impacted relative to controls maintained with aTc,
529 indicating EXP1 is not important at this early stage; rather cultures developed normally until a
530 late stage when parasites arrested predominantly as trophozoites and schizonts and failed to
531 complete the cycle (Figure 5A). We compared these developmental defects with those following
532 inactivation of protein export and PVM channel activity in EXP2^{apt}, an EXP2 conditional mutant
533 that we previously generated using the same dual aptamer TDA approach (14). EXP2^{apt}
534 parasites grown without aTc arrested at an earlier trophozoite stage that was distinct from
535 EXP1-depleted parasites, suggesting EXP2-dependent transport activities are not impacted by
536 loss of EXP1 (Figure 5B).

537 To directly test this, we monitored protein export beyond the PVM in EXP1^{apt} and
538 EXP2^{apt} parasites using the above experimental design of removing aTc from synchronized,
539 purified trophozoites and then analyzing export by IFA at the midpoint of the following cycle.
540 While EXP2 knockdown results in a robust block in export of SBP1 as previously reported (14),

541 no defect in SBP1 export was observed following knockdown of EXP1 (Figure 5C,D). Rather,
542 SBP1 export was more robust in the absence of aTc as measured by mean fluorescent intensity
543 in the infected RBC compartment or the number of SBP1-positive Mauer's clefts (punctate
544 structures beyond the PVM) per infected RBC (Figure 5C). While the basis for the apparent
545 increase in exported SBP1 signal is unclear, these results clearly indicate EXP1 is not required
546 for protein export.

547 To better understand the impact of EXP1 depletion in late stage parasites, we next
548 examined parasite ultrastructure by transmission electron microscopy (TEM). As seen in the
549 parental line and EXP1^{apt} grown with aTc, the PVM normally tightly overlays the PPM (Figure
550 6A,B). In contrast, EXP1^{apt} parasites grown 48 hours without aTc displayed striking changes in
551 PV morphology with increased separation between the PVM and PPM in both trophozoites and
552 segmented schizonts (Figure 6C-E). Curiously, the lumen of these enlarged PVs often
553 contained additional membrane-enclosed structures filled with host cytosol (Figure 6D, double
554 arrowheads). Additionally, membrane structures in the host cell cytosol external to the PVM
555 (Figure 6B, enlarged region) which likely represent portions of the tubulovesicular network
556 (TVN) were observed with increasing frequency upon EXP1 depletion. Quantification of
557 morphological abnormalities observed by TEM in two independent experiments is shown in
558 Table 2.

559 In EXP1^{apt} parasites that displayed increased separation between PVM and PPM, the
560 enlarged PV lumen often showed equivalent density with the host cytosol, possibly indicating a
561 broken vacuole (Figure 6C,E). To ascertain if PVM integrity was compromised following EXP1
562 knockdown, we fused a signal peptide to the fluorescent protein mRuby3 to target it to the PV
563 and expressed it under the control of the *exp2* promoter in the EXP1^{apt} line. Parasites depleted
564 of EXP1 continued to show concentrated mRuby3 signal at the cell periphery, indicating the
565 PVM is not compromised, despite altered PVM ultrastructure (Figure 6F).

566

567 **EXP1 is required for proper organization of EXP2 in the PVM**

568 To further investigate alterations in the PV, we evaluated the impact of EXP1 knockdown
569 on other PVM proteins. As expected from the observation that protein export remains
570 operational in EXP1^{apt}, depletion of EXP1 did not substantially alter EXP2 levels (Figure 7A). To
571 monitor EXP2 distribution in EXP1^{apt} parasites, we introduced a C-terminal mNG fusion on the
572 endogenous copy of EXP2 and imaged parasites at a late stage corresponding with
573 developmental arrest. Live fluorescent analysis of a parental EXP2-mNG control line with an
574 unmodified *exp1* locus (29) showed a punctate distribution at early stages that often resolved
575 into several larger patches in trophozoites and schizonts (Figure 7B). In contrast, EXP2
576 distribution was substantially altered in EXP1^{apt}::EXP2-mNG parasites, often concentrating into
577 one or two discrete points along the PVM (Figure 7B). To quantify this altered localization of
578 EXP2-mNG, BODIPY-TR-Ceramide labeling was used as a guide to trace the PVM and collect
579 EXP2-mNG signal along the PVM circumference (Figure 7B). Analysis of these PVM traces
580 showed that the number of discrete EXP2 signal patches around the PVM was significantly
581 reduced in EXP1^{apt} parasites with EXP2 signal concentrated into a smaller proportion of the
582 PVM circumference (Figure 7C,D). These results show that although EXP2 function is
583 preserved following depletion of EXP1, its organization in the PVM is drastically altered.

584

585 **Discussion**

586 Promiscuous biotin ligases have emerged as powerful tools for proximity-based protein
587 identification in live cells (48). To date, the original *E. coli* BirA* (BioID) has been employed by
588 four studies in *Plasmodium spp.*, including two that targeted BioID to the PV (49-52). Khosh-
589 Naucke and colleagues targeted a signal peptide-GFP-BirA* fusion to the *P. falciparum* PV
590 lumen (50) while Schnider and colleagues utilized a second copy of EXP1 with a C-terminal
591 BirA* fusion to probe the PV in *P. berghei* (51). In the present study, we present the first use of
592 BioID2 in *Plasmodium spp.*, which we fused to the endogenous copy of EXP2 or HSP101 to

593 identify proteins at the luminal face of the PVM. The ability to fuse mNG or BioID2 but not BioID
594 to EXP2 indicates EXP2 will not tolerate larger bulky fusions, possibly due to defects in
595 trafficking, oligomerization or assembly with other PTEX components, demonstrating that the
596 smaller size of BioID2 offers advantages over the original BioID system. We have also adapted
597 a Cpf1 editing system for use in *P. falciparum* which facilitated successful genome editing with
598 the same efficiency as our Cas9 editing system. Since the discovery of its T-rich PAM
599 requirements, Cpf1 has been suggested to possess unique promise for manipulation of the A+T
600 rich genomes of *Plasmodium spp.* (32). To our knowledge, this is the first report of Cpf1 use in
601 malaria parasites, realizing that potential of greatly expanding the repertoire of gRNA targets
602 available to manipulate the *P. falciparum* genome.

603 While we expect the EXP2-BioID2 and HSP101-BioID2 datasets to contain novel PV
604 and PVM proteins (Figure S1C) and are currently working to validate these candidates, we have
605 focused in the present study on functional analysis of EXP1, one of the highest-ranking proteins
606 in our proteomics. The study of EXP1 dates back more than 35 years when a monoclonal
607 antibody shown to label the PVM (40, 53, 54) was subsequently found to detect an antigen in
608 the EXP1 C-terminus (43). However, despite being one of the earliest discovered PVM proteins,
609 EXP1 function has remained obscure. Previous failed attempts to disrupt the *exp1* gene in *P.*
610 *falciparum* (55) and *P. berghei* (56) indicated a critical role for EXP1 during the blood stage.
611 EXP1 is also expressed and localized to the PVM in the parasite liver stage (57) and a C-
612 terminal region of *P. berghei* EXP1 has been shown to interact with rodent and human
613 Apolipoprotein H (56). While this interaction is important for *P. berghei* development within
614 hepatocytes, it could not be recapitulated in yeast two-hybrid assays with *P. falciparum* EXP1,
615 which displays low sequence identity with *P. berghei* EXP1 in the C-terminal region critical for
616 interaction with Apolipoprotein H, possibly indicating lineage-specific EXP1 adaptations.

617 In the present study, we found that blood stage function of *P. falciparum* EXP1 is
618 compromised by a C-terminal fusion to mNG. The topology of EXP1 orients the C-terminus on

619 the host cytosolic face of the PVM while the N-terminus is positioned within the PV lumen (15,
620 16). As EXP1 bearing a bulkier mDHFR-GFP C-terminal fusion is still inserted into the PVM with
621 proper topology (58), the EXP1-mNG defect seems unlikely to result from a perturbation in
622 trafficking. The mNG fusion may interfere with interactions that enable EXP1 to organize into
623 oligomeric arrays (22) as the C-terminus of *P. berghei* SEP/ETRAMP family members have
624 been shown to be important for oligomer formation (19). However, the entire C-terminal domain
625 of *P. berghei* EXP1 has recently been shown to be dispensable during the blood stage
626 (although it is important in both the mosquito vector and in the hepatocyte where truncated
627 EXP1 fails to properly traffic to the PVM, illustrating distinct EXP1 functional roles and trafficking
628 constraints between parasite life stages) (59). The inability to similarly truncate the EXP1 N-
629 terminus in *P. berghei* implies its essential blood stage function occurs within the PV lumen (59).

630 *An in silico* approach to discovery of gene function through analysis of gene
631 relationships over large evolutionary distance suggested EXP1 may be a membrane GST (20).
632 Subsequent *in vitro* experiments found recombinant EXP1 to possess GST activity, particularly
633 toward hemozoin, leading to a model where EXP1 provides protection from the oxidative stress
634 that results from catabolism of hemoglobin within endocytic vesicles and the digestive vacuole
635 (20). While enzymes involved in hemoglobin degradation such as plasmepsin aspartic
636 proteases do traffic through the PV to reach the digestive vacuole, their PV residence is
637 transient with principal localization observed in the digestive vacuole (60). In contrast, the vast
638 majority of EXP1 is localized at the PVM, suggesting this is the principal site of function. Here,
639 we found that a version of EXP1 bearing an R70T mutation, which reduced recombinant EXP1
640 GST activity more than fivefold *in vitro*, can rescue parasite growth ~70% as well as the wild
641 type protein upon knockdown of endogenous EXP1 (Figure 4C). These results strongly suggest
642 that the proposed GST activity does not fully account for the essential blood stage function of *P.*
643 *falciparum* EXP1.

644 Known essential functions that manifest defects at the PVM include inactivation of
645 protein export and small molecule transport following knockdown of PTEX components (8, 9,
646 14, 61) and RON3 (62) or a block in egress following knockdown of key players in the protease
647 cascade that mediates PVM destruction at the end of the cycle (36, 63, 64). Parasites depleted
648 of EXP1 do not display an export defect and develop to a late stage where they arrest mainly as
649 trophozoites, suggesting EXP1 does not function directly in egress (Figure 5). Arrested
650 parasites produced additional membrane structures in the host cytosol, likely reflecting
651 alterations in the TVN, an extension of the PVM thought to function in nutrient acquisition to
652 which EXP1 is partially localized (65-67). Parasites depleted of EXP1 also displayed an
653 enlarged PV lumen that was often filled with hemoglobin-containing membrane-bound
654 structures (Figure 6D). These structures are reminiscent of TVN enclosures of host cytosol (68-
655 71) except that they are present within the PVM, and may thus reflect abnormalities in TVN
656 formation. Alternatively, these structures might result from irregularities of the central cavity, a
657 poorly understood structure open to the host cytosol and often observed as an indentation at the
658 parasite periphery (72, 73). Notably, cytostomes remained visible in EXP1 knockdown parasites
659 despite these alterations (Figure 6C,D, arrowheads). Defects in uptake of host cell cytosol
660 would be expected to manifest in the terminal pathway compartment, the digestive vacuole, as
661 observed with a VPS45 conditional mutant that prevents delivery of endocytosed material to the
662 digestive vacuole, severely limiting hemoglobin degradation (74). However, digestive vacuoles
663 appeared largely normal and hemozoin crystal formation was not grossly altered following EXP1
664 knockdown (Figure 5A and 6), suggesting uptake of host cell cytosol is not critically impacted.

665 Reduction of EXP1 levels also produced a striking change in EXP2 distribution with
666 EXP2 often concentrated to one or two discrete points along the PVM (Figure 7). EXP2 forms a
667 dual functional pore in the PVM that is required for small molecule transport and effector protein
668 translocation (10, 14). Although we did not directly evaluate small molecule transport at the
669 PVM, the fact that EXP2 pore function in protein export within PTEX is not impaired and that

670 EXP1 knockdown parasites do not arrest at an earlier developmental stage suggests that EXP2-
671 dependent small molecule transport is unlikely to be critically impacted.

672 A striking feature of the PVM is its intimate apposition to the PPM but the basis for
673 maintaining this proximity is not known. When protein export is disabled by inactivating PTEX
674 components, tubular distensions form and project into the host cell (14). This PV swelling
675 appears to result from accumulation of blocked exported proteins within the PV but occurs at
676 discrete points, with PVM-PPM anchoring still largely maintained (14). In contrast, the more
677 uniform separation between PVM and PPM observed upon EXP1 knockdown may indicate a
678 role for EXP1 in maintaining this intimate membrane connection, loss of which might result in
679 broad disorganization of PVM patterning that is somehow tied to the connection with the PPM.
680 Developmental arrest in late stage parasites may reflect a critical, though currently unclear,
681 requirement for maintenance of this connection for proper completion of schizogony. In
682 conclusion, our results call into question the importance of GST activity for EXP1 function and
683 reveal a critical requirement for EXP1 in maintaining proper PVM/TVN organization.

684

685 **Acknowledgements**

686 This work was supported by National Institutes of Health grant HL133453 to J.R.B. The funders
687 had no role in study design, data collection and interpretation, or the decision to submit the work
688 for publication.

689 We thank J. Aguiar for the EXP1 antibody, J. McBride, D. Cavanaugh and EMRR for the EXP2
690 antibody, C. Braun-Breton for the SBP1 antibody, W. Beatty, K. Hausmann and the WUSTL
691 Molecular Microbiology Imaging Facility for assistance with electron microscopy, B. Vaupel for
692 assistance with molecular cloning and E. Istvan and A. Polino for assistance with parasite
693 culture.

694

695 **Author contributions**

696 T.N., J.M.B., D.E.G. and J.R.B. conceived and designed the experiments. T.N., J.M.B., S.R.,
697 Y.J. and J.R.B. performed the experiments. T.N., J.M.B., S.R., Y.J., J.A.W., D.E.G. and J.R.B.
698 analyzed the data. J.R.B. oversaw the project and wrote the manuscript. All authors discussed
699 and edited the manuscript.

700

701 **Figures Legends**

702

703 **Figure 1: BioID2 identifies the protein contents of the PV/PVM.** (A) Schematic showing C-
704 terminal BioID2-3xHA fusion to the endogenous *exp2* and *hsp101* genes. (B)
705 Immunofluorescence assay of parental, EXP2-BioID2 and HSP101-BioID2 parasites grown in
706 media supplemented with 200 μ M biotin. Scale bars are 5 μ m. (C) Western blot of parental,
707 EXP2-BioID2 and HSP101-BioID2 lines grown in regular RPMI (which contains 820 nM biotin,
708 designated “-”) or 18 hours in RPMI supplemented with 200 μ M biotin (designated “+”).
709 Molecular weights after signal peptide cleavage are predicted to be 61.2 kDa for EXP2-BioID2-
710 3xHA and 130 kDa for HSP101-BioID2-3xHA. Arrowheads from top to bottom indicate bands
711 expected to correspond to untagged PTEX150 and HSP101. Arrow indicates prominent band at
712 ~23 kDa. (D) Ven diagram summarizing overlapping and distinct proteins detected in EXP2-
713 BioID2 and HSP101-BioID2 datasets. All proteins identified in untagged negative controls were
714 removed from the BioID2 datasets and remaining proteins that were present in both
715 independent replicates of EXP2-BioID2 or HSP101-BioID2 were used to generate the diagram.
716 (E) Western blot as in (C) probed with anti-EXP1 to show correspondence with prominent ~23
717 kDa band. Molecular weight after signal peptide cleavage is predicted to be 14.7 kDa for EXP1.
718 Note that EXP1 is observed to migrate at a higher molecular weight than predicted.

719

720 **Figure 2: Genome editing of the *exp1* locus with Cpf1.** (A) Schematic showing strategy for
721 double homologous recombination repair of double-strand breaks mediated by Cas9 or Cpf1 at

722 the 3' end of *exp1*. Individual gRNA target sequences are shown in the zoomed view in the
723 dashed box. Exon sequences are shown in uppercase while intron and UTR sequences are
724 shown in lowercase. 3' UTR, 3' untranslated region; yDHODH, yeast dihydroorotate
725 dehydrogenase; PAM, protospacer adjustment motif. (B) Diagnostic PCR with primers indicated
726 in the schematic and Western blot showing successful integration at the 3' end of *exp1*
727 mediated by either Cas9 or Cpf1. Aldolase serves as a loading control. Molecular weight after
728 signal peptide cleavage is predicted to be 20.9 kDa for EXP1-3xHA-GFP11. Note that EXP1
729 and derivative fusions are observed to migrate at a higher molecular weight than predicted.
730

731 **Figure 3: Lethal EXP1 knockdown with a dual aptamer strategy.** (A) Schematic of modified
732 *exp1* locus and TDA control of translation in EXP1^{apt} parasites. 2A, *Thosea asigna* virus 2A skip
733 peptide; BSD, blasticidin-S deaminase. (B) Western blot of parental parasite line grown without
734 aTc and EXP1^{apt} parasites grown 48 hours with or without aTc. Aldolase serves as a loading
735 control. Molecular weights after signal peptide cleavage are predicted to be 14.7 kDa for EXP1
736 and 18 kDa for EXP1-3xHA. Note that EXP1 and derivative fusions are observed to migrate at a
737 higher molecular weight than predicted. Results are representative of three independent
738 experiments. (C) Growth analysis of parental and EXP1^{apt} parasites with or without aTc. Results
739 from one experiment with three technical replicates plotted are shown. The scatter plot shows
740 the slope of the line fitted to the mean of log₂-transformed parasitemias for each of three
741 independent experiments. Error bars indicate SEM. P values were determined by an unpaired,
742 two-sided Student's t-test.

743

744 **Figure 4: EXP1 *in vivo* function is ablated by a bulky C-terminal fusion but not by**
745 **mutation of a residue important for GST activity *in vitro*.** (A) Schematic showing
746 complementing versions of EXP1 introduced into EXP1^{apt}. (B) Western blot of parent, EXP1^{apt}
747 and complemented lines. Two independently complemented lines were generated with each

748 construct and are designated A or B. Aldolase serves as a loading control. Molecular weights
749 after signal peptide cleavage are predicted to be 18 kDa for EXP1-3xHA, 19.2 kDa for EXP1-
750 WT-3xMYC and EXP1-R70T-3xMYC and 46.2 kDa for EXP1-mNG-3xMYC. Note that EXP1 and
751 derivative fusions are observed to migrate at a higher molecular weight than predicted. (C)
752 Growth analysis of complemented EXP1^{apt} lines with or without aTc. The scatter plot shows the
753 slope of the line fitted to the mean of log₂-transformed parasitemias for four (EXP1-WT-
754 3xMYC), five (EXP1-R70T-3xMYC) or six (EXP1-mNG-3xMYC) independent experiments.
755 Means from independently generated lines complemented with the same version of EXP1 were
756 pooled and are distinguished by different symbols (circles and triangles). Error bars indicate
757 SEM. P values were determined by an unpaired, two-sided Student's t-test. (D)
758 Immunofluorescence assay of EXP1^{apt} complemented lines. Scale bars are 5 μm.

759

760 **Figure 5: Depletion of EXP1 results in late cycle arrest but does not impact protein**

761 **export.** (A-B) Quantification of parasite stages of development from Giemsa-stained thin
762 smears of (A) EXP1^{apt} and (B) EXP2^{apt} parasites synchronized to a 10-hour window and grown
763 with or without aTc. Time 0 hours indicates the point of aTc removal at which purified late
764 trophozoites (~32-42 hours post-invasion) were mixed with fresh uninfected RBCs. Results from
765 one experiment performed in technical triplicate are shown and are representative of two
766 independent experiments. Error bars indicate SD. Representative images of the majority
767 parasite population at each time point are shown. Scale bars are 2 μm. (C-D)
768 Immunofluorescence assay showing SBP1, which is exported to the Maurer's clefts, in (C)
769 EXP1^{apt} and (D) EXP2^{apt} parasites. Quantification of SBP1 export beyond the PVM (both
770 EXP1^{apt} and EXP2^{apt} contain a 3xFLAG tag on HSP101 which was used as a marker for the
771 PVM) is shown as MFI of SBP1 within the host compartment or as the number of SBP1-positive
772 puncta (Maurer's clefts) within the host compartment. Merged images of SBP1, FLAG and DAPI
773 signal are shown. The dashed line indicates the boundary of the host RBC traced from the

774 corresponding DIC image. Data are pooled from three independent experiments and n is the
775 number of individual parasite-infected RBCs. Boxes and whiskers delineate 25th-75th and 10th-
776 90th percentiles, respectively. P values were determined by an unpaired, two-sided Student's t-
777 test. MFI, mean fluorescence intensity; AU, arbitrary units. Scale bars are 2 μ m.

778

779 **Figure 6: Depletion of EXP1 results in PV/PVM morphological abnormalities.** (A-E) TEM
780 visualization of parasite ultrastructure in parent and EXP1^{apt} parasites grown 48 hours with or
781 without aTc. Images are shown of (A-D) trophozoites and (E) segmented schizonts. Dashed
782 boxes indicate enlarged areas shown to the right. Arrows indicate PVM and PPM. Arrowheads
783 indicate cytostomes. Double arrowheads indicate abnormal membrane-enclosed structures
784 filled with host cytosol in the PV lumen. Results are representative of two independent
785 experiments. Quantification of morphological abnormalities is shown in Table 2. Scale bars are
786 500 nm. (F) Live fluorescence imaging of magnet-purified EXP1^{apt}::PV-mRuby3 parasites grown
787 48 hours with or without aTc. The dashed lines indicate the boundary of infected RBC traced
788 from the corresponding DIC image. Results are representative of three independent
789 experiments. Scale bars are 5 μ m.

790

791 **Figure 7: Depletion of EXP1 alters EXP2 distribution in the PVM.** (A) Western blot of
792 parental parasite line grown without aTc and EXP1^{apt} parasites grown 48 hours with or without
793 aTc. Aldolase serves as a loading control. Molecular weights after signal peptide cleavage are
794 predicted to be 30.8 kDa for EXP2 and 18 kDa for EXP1-3xHA. Note that EXP1 and derivative
795 fusions are observed to migrate at a higher molecular weight than predicted. (B) Live
796 fluorescent images of EXP2-mNG and EXP1^{apt}::EXP2-mNG parasites grown 48 hours with or
797 without aTc. Merged images include EXP2-mNG signal in green together with DIC and BODIPY
798 TR Ceramide signal in red used to trace the PVM. Scale bars are 2 μ m. The corresponding
799 histograms of EXP2-mNG signal along the PVM trace are shown for each cell. Dashed line is

800 the mean of the minimum and maximum EXP2-mNG signal intensity. (C) Quantification of the
801 number of discrete peaks of EXP2-mNG signal exceeding the mean signal threshold as shown
802 in (B) for EXP2-mNG and EXP1^{apt}::EXP2-mNG parasites grown 48 hours with or without aTc.
803 Data are pooled from three independent experiments and *n* is the number of individual
804 parasites. Boxes and whiskers delineate 25th-75th and 10th-90th percentiles, respectively. P
805 values were determined by an unpaired, two-sided Student's t-test. (D) Graph showing the
806 minimum distance along the PVM (given as a percent of total PVM length) containing the
807 indicated amounts of EXP2-mNG fluorescent signal (given as percent of total EXP2-mNG signal
808 per trace) in EXP2-mNG and EXP1^{apt}::EXP2-mNG parasites grown 48 hours with or without
809 aTc. Data points are means from three independent experiments fitted to a smooth line.

810 **Figure S1: Generation of the EXP2-BioID2 fusion line and expression profiles of select**
811 **hits.** (A) Western blot of parent and EXP2-BioID2-3xHA parasites. Molecular weights after
812 signal peptide cleavage are predicted to be 30.8 kDa for EXP2 and 61.2 kDa for EXP2-BioID2-
813 3xHA. (B) Transcript fold change throughout intraerythrocytic development assessed by
814 transcriptomic analysis of synchronized *P. falciparum* 3D7 parasites for EXP2, HSP101, EXP1
815 and select ETRAMP family members. Data are from RNAseq analysis by Otto and colleagues
816 (75). Genes with similar expression pattern to *exp2* are shown in color. (C) Ven diagram
817 summarizing overlapping and distinct proteins detected in EXP2-BioID2, HSP101-BioID2 and
818 SP-GFP-BirA* datasets (50). Data from Khosh-Naucke et al 2018 was processed in the same
819 way as the BioID2 datasets in this study by pooling SP-GFP-BirA* mass spectrometry datasets
820 obtained from saponin supernatant and pellet fractions and removing all proteins identified in
821 3D7 negative controls.

822

823 **Figure S2: Genome editing of *exp1*, *etramp10.2* and *etramp5* with Cpf1.** (A) Western blot of
824 parent and EXP1-3xHA-GFP11 fusion parasites generated with AsCpf1 or LbCpf1 and gRNA2
825 as shown in Figure 2A but expressed from the selectable pUF-AsCpf1 or pUF-LbCpf1 plasmids
826 that contain a yDHODH cassette. Aldolase serves as a loading control. Molecular weight after
827 signal peptide cleavage is predicted to be 20.9 kDa for EXP1-3xHA-GFP11. Note that EXP1
828 and derivative fusions are observed to migrate at a higher molecular weight than predicted. (B)
829 Schematic showing strategy for double homologous recombination repair of double-strand
830 breaks mediated by Cpf1 at the 3' end of the *etramp10.2* and *etramp5* genes to install a 3xHA
831 fusion and 3' TetR-DOZI-aptamers. 3' UTR, 3' untranslated region; yDHODH, yeast
832 dihydroorotate dehydrogenase. (C,D) Sequence of the 3' end of *etramp10.2* or *etramp5* with
833 Cpf1 gRNA target indicated. Successful integration mediated by AsCpf1 to generate a 3' fusion
834 to 3xHA is shown by diagnostic PCR with primers indicated in the schematic and by Western
835 blot of ETRAMP10.2^{apt} and ETRAMP5^{apt} parasites grown with or without 1 μ M aTc for 96 hours.
836 EXP2 serves as a loading control. Molecular weight after signal peptide cleavage is predicted to
837 be 39.6 kDa for ETRAMP10.2-3xHA and 19.6 kDa for ETRAMP5-3xHA. Similar to EXP1, both
838 ETRAMP10.2-3xHA and ETRAMP5-3xHA are observed to migrate at a higher molecular weight
839 than predicted. PAM, protospacer adjustment motif.

840

841 **Figure S3: Generation of EXP1^{apt} parasites and analysis of DiCre-mediated *exp1* excision.**

842 (A) Schematic for strategy used to replace the endogenous *exp1* coding sequence with a re-
843 coded version of *exp1* with TDA and DiCre elements by Cpf1 editing and double homologous
844 recombination. (B) Diagnostic PCR with primers indicated in the schematic in (A) showing
845 successful integration at the 5' and 3' ends of the *exp1* locus in EXP1^{apt} parasites. The absence
846 of the product in EXP1^{apt} using primers P65/P67 is likely due to the very large amplicon size. (C)
847 Schematic of *exp1* locus following excision between *loxP* sites by DiCre. The pEXP1^{apt} plasmid
848 was designed so that DiCre excision of the modified locus would place the promoter-less

849 *mruby3* coding sequence under the control of the endogenous *exp1* promoter. (D) Growth
850 analysis of parental and EXP1^{apt} parasites with or without 1 μ M aTc or with and without 100 μ M
851 or 250 μ M rapamycin. The scatter plot shows the slope of the line fitted to the mean of log2-
852 transformed parasitemias for each of three independent experiments. Error bars indicate SEM.
853 (E) Diagnostic PCR for *exp1* excision by DiCre with primers indicated in the schematics.

854

855 References

- 856 1. Lingelbach K, Joiner KA. 1998. The parasitophorous vacuole membrane surrounding
857 Plasmodium and Toxoplasma: an unusual compartment in infected cells. *J Cell Sci* 111 (
858 Pt 11):1467-75.
- 859 2. Sherling ES, van Ooij C. 2016. Host cell remodeling by pathogens: the exomembrane
860 system in Plasmodium-infected erythrocytes. *FEMS Microbiol Rev* 40:701-21.
- 861 3. Aikawa M, Hepler PK, Huff CG, Sprinz H. 1966. The feeding mechanism of avian
862 malarial parasites. *J Cell Biol* 28:355-73.
- 863 4. Francis SE, Sullivan DJ, Goldberg DE. 1997. Hemoglobin metabolism in the malaria
864 parasite Plasmodium falciparum. *Annu Rev Microbiol* 51:97-123.
- 865 5. Lew VL, Tiffert T, Ginsburg H. 2003. Excess hemoglobin digestion and the osmotic
866 stability of Plasmodium falciparum-infected red blood cells. *Blood* 101:4189-94.
- 867 6. Hanssen E, Knoechel C, Dearnley M, Dixon MW, Le Gros M, Larabell C, Tilley L. 2012.
868 Soft X-ray microscopy analysis of cell volume and hemoglobin content in erythrocytes
869 infected with asexual and sexual stages of Plasmodium falciparum. *J Struct Biol*
870 177:224-32.
- 871 7. de Koning-Ward TF, Gilson PR, Boddey JA, Rug M, Smith BJ, Papenfuss AT, Sanders
872 PR, Lundie RJ, Maier AG, Cowman AF, Crabb BS. 2009. A newly discovered protein
873 export machine in malaria parasites. *Nature* 459:945-9.
- 874 8. Elsworth B, Matthews K, Nie CQ, Kalanon M, Charnaud SC, Sanders PR, Chisholm SA,
875 Counihan NA, Shaw PJ, Pino P, Chan JA, Azevedo MF, Rogerson SJ, Beeson JG,
876 Crabb BS, Gilson PR, de Koning-Ward TF. 2014. PTEX is an essential nexus for protein
877 export in malaria parasites. *Nature* 511:587-91.
- 878 9. Beck JR, Muralidharan V, Oksman A, Goldberg DE. 2014. PTEX component HSP101
879 mediates export of diverse malaria effectors into host erythrocytes. *Nature* 511:592-5.
- 880 10. Ho CM, Beck JR, Lai M, Cui Y, Goldberg DE, Egea PF, Zhou ZH. 2018. Malaria parasite
881 translocon structure and mechanism of effector export. *Nature* 561:70-75.
- 882 11. Gehde N, Hinrichs C, Montilla I, Charpian S, Lingelbach K, Przyborski JM. 2009. Protein
883 unfolding is an essential requirement for transport across the parasitophorous vacuolar
884 membrane of Plasmodium falciparum. *Mol Microbiol* 71:613-28.
- 885 12. Desai SA, Krogstad DJ, McCleskey EW. 1993. A nutrient-permeable channel on the
886 intraerythrocytic malaria parasite. *Nature* 362:643-6.
- 887 13. Desai SA, Rosenberg RL. 1997. Pore size of the malaria parasite's nutrient channel.
888 *Proc Natl Acad Sci U S A* 94:2045-9.
- 889 14. Garten M, Nasamu AS, Niles JC, Zimmerberg J, Goldberg DE, Beck JR. 2018. EXP2 is
890 a nutrient-permeable channel in the vacuolar membrane of Plasmodium and is essential
891 for protein export via PTEX. *Nat Microbiol* 3:1090-1098.

- 892 15. Günther K, Tümmler M, Arnold HH, Ridley R, Goman M, Scaife JG, Lingelbach K. 1991.
893 An exported protein of *Plasmodium falciparum* is synthesized as an integral membrane
894 protein. *Mol Biochem Parasitol* 46:149-57.
- 895 16. Ansorge I, Benting J, Bhakdi S, Lingelbach K. 1996. Protein sorting in *Plasmodium*
896 *falciparum*-infected red blood cells permeabilized with the pore-forming protein
897 streptolysin O. *Biochem J* 315 (Pt 1):307-14.
- 898 17. Spielmann T, Ferguson DJ, Beck HP. 2003. etramps, a new *Plasmodium falciparum*
899 gene family coding for developmentally regulated and highly charged membrane
900 proteins located at the parasite-host cell interface. *Mol Biol Cell* 14:1529-44.
- 901 18. Spielmann T, Beck HP. 2000. Analysis of stage-specific transcription in *Plasmodium*
902 *falciparum* reveals a set of genes exclusively transcribed in ring stage parasites. *Mol*
903 *Biochem Parasitol* 111:453-8.
- 904 19. Currà C, Pace T, Franke-Fayard BM, Picci L, Bertuccini L, Ponzi M. 2012. Erythrocyte
905 remodeling in *Plasmodium berghei* infection: the contribution of SEP family members.
906 *Traffic* 13:388-99.
- 907 20. Lisewski AM, Quiros JP, Ng CL, Adikesavan AK, Miura K, Putluri N, Eastman RT,
908 Scandfeld D, Regenbogen SJ, Altenhofen L, Llinás M, Sreekumar A, Long C, Fidock DA,
909 Lichtarge O. 2014. Supergenomic network compression and the discovery of EXP1 as a
910 glutathione transferase inhibited by artesunate. *Cell* 158:916-928.
- 911 21. Glushakova S, Beck JR, Garten M, Busse BL, Nasamu AS, Tenkova-Heuser T, Heuser
912 J, Goldberg DE, Zimmerberg J. 2018. Rounding precedes rupture and breakdown of
913 vacuolar membranes minutes before malaria parasite egress from erythrocytes. *Cell*
914 *Microbiol* 20:e12868.
- 915 22. Spielmann T, Gardiner DL, Beck HP, Trenholme KR, Kemp DJ. 2006. Organization of
916 ETRAMPs and EXP-1 at the parasite-host cell interface of malaria parasites. *Mol*
917 *Microbiol* 59:779-94.
- 918 23. Wickham ME, Rug M, Ralph SA, Klonis N, McFadden GI, Tilley L, Cowman AF. 2001.
919 Trafficking and assembly of the cytoadherence complex in *Plasmodium falciparum*-
920 infected human erythrocytes. *EMBO J* 20:5636-49.
- 921 24. Riglar DT, Rogers KL, Hanssen E, Turnbull L, Bullen HE, Charnaud SC, Przyborski J,
922 Gilson PR, Whitchurch CB, Crabb BS, Baum J, Cowman AF. 2013. Spatial association
923 with PTEX complexes defines regions for effector export into *Plasmodium falciparum*-
924 infected erythrocytes. *Nat Commun* 4:1415.
- 925 25. Bullen HE, Charnaud SC, Kalanon M, Riglar DT, Dekiwadia C, Kangwanrangsang N, Torii
926 M, Tsuboi T, Baum J, Ralph SA, Cowman AF, de Koning-Ward TF, Crabb BS, Gilson
927 PR. 2012. Biosynthesis, localization, and macromolecular arrangement of the
928 *Plasmodium falciparum* translocon of exported proteins (PTEX). *J Biol Chem* 287:7871-
929 84.
- 930 26. Charnaud SC, Jonsdottir TK, Sanders PR, Bullen HE, Dickerman BK, Kouskousis B,
931 Palmer CS, Pietrzak HM, Laumaea AE, Erazo AB, McHugh E, Tilley L, Crabb BS, Gilson
932 PR. 2018. Spatial organization of protein export in malaria parasite blood stages. *Traffic*
933 19:605-623.
- 934 27. Adisa A, Rug M, Klonis N, Foley M, Cowman AF, Tilley L. 2003. The signal sequence of
935 exported protein-1 directs the green fluorescent protein to the parasitophorous vacuole
936 of transfected malaria parasites. *J Biol Chem* 278:6532-42.
- 937 28. Kim DI, Jensen SC, Noble KA, Kc B, Roux KH, Motamedchaboki K, Roux KJ. 2016. An
938 improved smaller biotin ligase for BioID proximity labeling. *Mol Biol Cell* 27:1188-96.
- 939 29. Glushakova S, Busse BL, Garten M, Beck JR, Fairhurst RM, Goldberg DE, Zimmerberg
940 J. 2017. Exploitation of a newly-identified entry pathway into the malaria parasite-
941 infected erythrocyte to inhibit parasite egress. *Sci Rep* 7:12250.

- 942 30. Ganesan SM, Morrisey JM, Ke H, Painter HJ, Laroia K, Phillips MA, Rathod PK, Mather
943 MW, Vaidya AB. 2011. Yeast dihydroorotate dehydrogenase as a new selectable marker
944 for *Plasmodium falciparum* transfection. *Mol Biochem Parasitol* 177:29-34.
- 945 31. Spillman NJ, Beck JR, Ganesan SM, Niles JC, Goldberg DE. 2017. The chaperonin
946 TRiC forms an oligomeric complex in the malaria parasite cytosol. *Cell Microbiol* 19.
- 947 32. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler
948 P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F. 2015. Cpf1 is a
949 single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* 163:759-71.
- 950 33. Ganesan SM, Falla A, Goldfless SJ, Nasamu AS, Niles JC. 2016. Synthetic RNA-protein
951 modules integrated with native translation mechanisms to control gene expression in
952 malaria parasites. *Nat Commun* 7:10727.
- 953 34. Chen AL, Kim EW, Toh JY, Vashisht AA, Rashoff AQ, Van C, Huang AS, Moon AS, Bell
954 HN, Bentolila LA, Wohlschlegel JA, Bradley PJ. 2015. Novel components of the
955 *Toxoplasma* inner membrane complex revealed by BioID. *MBio* 6:e02357-14.
- 956 35. Yap A, Azevedo MF, Gilson PR, Weiss GE, O'Neill MT, Wilson DW, Crabb BS, Cowman
957 AF. 2014. Conditional expression of apical membrane antigen 1 in *Plasmodium*
958 *falciparum* shows it is required for erythrocyte invasion by merozoites. *Cell Microbiol*
959 16:642-56.
- 960 36. Nasamu AS, Glushakova S, Russo I, Vaupel B, Oksman A, Kim AS, Fremont DH, Tolia
961 N, Beck JR, Meyers MJ, Niles JC, Zimmerberg J, Goldberg DE. 2017. Plasmepsins IX
962 and X are essential and druggable mediators of malaria parasite egress and invasion.
963 *Science* 358:518-522.
- 964 37. Nkrumah LJ, Muhle RA, Moura PA, Ghosh P, Hatfull GF, Jacobs WR, Jr., Fidock DA.
965 2006. Efficient site-specific integration in *Plasmodium falciparum* chromosomes
966 mediated by mycobacteriophage Bxb1 integrase. *Nat Methods* 3:615-21.
- 967 38. Wohlschlegel JA. 2009. Identification of SUMO-conjugated proteins and their SUMO
968 attachment sites using proteomic mass spectrometry. *Methods Mol Biol* 497:33-49.
- 969 39. Florens L, Carozza MJ, Swanson SK, Fournier M, Coleman MK, Workman JL,
970 Washburn MP. 2006. Analyzing chromatin remodeling complexes using shotgun
971 proteomics and normalized spectral abundance factors. *Methods* 40:303-11.
- 972 40. Hall R, McBride J, Morgan G, Tait A, Zolg JW, Walliker D, Scaife J. 1983. Antigens of
973 the erythrocyte stages of the human malaria parasite *Plasmodium falciparum* detected
974 by monoclonal antibodies. *Mol Biochem Parasitol* 7:247-65.
- 975 41. Blisnick T, Morales Betoulle ME, Barale JC, Uzureau P, Berry L, Desroses S, Fujioka H,
976 Mattei D, Braun Breton C. 2000. Pfsbp1, a Maurer's cleft *Plasmodium falciparum* protein,
977 is associated with the erythrocyte skeleton. *Mol Biochem Parasitol* 111:107-21.
- 978 42. Batinovic S, McHugh E, Chisholm SA, Matthews K, Liu B, Dumont L, Charnaud SC,
979 Schneider MP, Gilson PR, de Koning-Ward TF, Dixon MWA, Tilley L. 2017. An exported
980 protein-interacting complex involved in the trafficking of virulence determinants in
981 *Plasmodium*-infected erythrocytes. *Nat Commun* 8:16044.
- 982 43. Hope IA, Mackay M, Hyde JE, Goman M, Scaife J. 1985. The gene for an exported
983 antigen of the malaria parasite *Plasmodium falciparum* cloned and expressed in
984 *Escherichia coli*. *Nucleic Acids Res* 13:369-79.
- 985 44. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A,
986 Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL,
987 Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea
988 M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH,
989 Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM,
990 Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM,
991 Barrell B. 2002. Genome sequence of the human malaria parasite *Plasmodium*
992 *falciparum*. *Nature* 419:498-511.

- 993 45. Kim D, Kim J, Hur JK, Been KW, Yoon SH, Kim JS. 2016. Genome-wide analysis
994 reveals specificities of Cpf1 endonucleases in human cells. *Nat Biotechnol* 34:863-8.
- 995 46. Kleinstiver BP, Tsai SQ, Prew MS, Nguyen NT, Welch MM, Lopez JM, McCaw ZR,
996 Aryee MJ, Joung JK. 2016. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases
997 in human cells. *Nat Biotechnol* 34:869-74.
- 998 47. Iriko H, Ishino T, Otsuki H, Ito D, Tachibana M, Torii M, Tsuboi T. 2018. *Plasmodium*
999 *falciparum* Exported Protein 1 is localized to dense granules in merozoites. *Parasitol Int*
1000 67:637-639.
- 1001 48. Trinkle-Mulcahy L. 2019. Recent advances in proximity-based labeling methods for
1002 interactome mapping. *F1000Res* 8.
- 1003 49. Kehrer J, Frischknecht F, Mair GR. 2016. Proteomic Analysis of the *Plasmodium berghei*
1004 Gametocyte Egressome and Vesicular bioID of Osmiophilic Body Proteins Identifies
1005 Merozoite TRAP-like Protein (MTRAP) as an Essential Factor for Parasite Transmission.
1006 *Mol Cell Proteomics* 15:2852-62.
- 1007 50. Khosh-Naucke M, Becker J, Mesen-Ramirez P, Kiani P, Birnbaum J, Frohke U,
1008 Jonscher E, Schluter H, Spielmann T. 2017. Identification of novel parasitophorous
1009 vacuole proteins in *P. falciparum* parasites using BioID. *Int J Med Microbiol*.
- 1010 51. Schnider CB, Bausch-Fluck D, Bruhlmann F, Heussler VT, Burda PC. 2018. BioID
1011 Reveals Novel Proteins of the *Plasmodium* Parasitophorous Vacuole Membrane.
1012 *mSphere* 3.
- 1013 52. Boucher MJ, Ghosh S, Zhang L, Lal A, Jang SW, Ju A, Zhang S, Wang X, Ralph SA,
1014 Zou J, Elias JE, Yeh E. 2018. Integrative proteomics and bioinformatic prediction enable
1015 a high-confidence apicoplast proteome in malaria parasites. *PLoS Biol* 16:e2005895.
- 1016 53. McBride JS, Walliker D, Morgan G. 1982. Antigenic diversity in the human malaria
1017 parasite *Plasmodium falciparum*. *Science* 217:254-7.
- 1018 54. Hope IA, Hall R, Simmons DL, Hyde JE, Scaife JG. 1984. Evidence for immunological
1019 cross-reaction between sporozoites and blood stages of a human malaria parasite.
1020 *Nature* 308:191-4.
- 1021 55. Maier AG, Rug M, O'Neill MT, Brown M, Chakravorty S, Szeszak T, Chesson J, Wu Y,
1022 Hughes K, Coppel RL, Newbold C, Beeson JG, Craig A, Crabb BS, Cowman AF. 2008.
1023 Exported proteins required for virulence and rigidity of *Plasmodium falciparum*-infected
1024 human erythrocytes. *Cell* 134:48-61.
- 1025 56. Sa ECC, Nyboer B, Heiss K, Sanches-Vaz M, Fontinha D, Wiedtke E, Grimm D,
1026 Przyborski JM, Mota MM, Prudencio M, Mueller AK. 2017. *Plasmodium berghei* EXP-1
1027 interacts with host Apolipoprotein H during *Plasmodium* liver-stage development. *Proc*
1028 *Natl Acad Sci U S A* 114:E1138-E1147.
- 1029 57. Sanchez GI, Rogers WO, Mellouk S, Hoffman SL. 1994. *Plasmodium falciparum*:
1030 exported protein-1, a blood stage antigen, is expressed in liver stage parasites. *Exp*
1031 *Parasitol* 79:59-62.
- 1032 58. Tribensky A, Graf AW, Diehl M, Fleck W, Przyborski JM. 2017. Trafficking of PExp1 to
1033 the parasitophorous vacuolar membrane of *Plasmodium falciparum* is independent of
1034 protein folding and the PTEX translocon. *Cell Microbiol* 19.
- 1035 59. Wolanin K, Fontinha D, Sanches-Vaz M, Nyboer B, Heiss K, Mueller AK, Prudêncio M.
1036 2019. A crucial role for the C-terminal domain of exported protein 1 during the mosquito
1037 and hepatic stages of the *Plasmodium berghei* life cycle. *Cell Microbiol*:e13088.
- 1038 60. Klemba M, Beatty W, Gluzman I, Goldberg DE. 2004. Trafficking of plasmepsin II to the
1039 food vacuole of the malaria parasite *Plasmodium falciparum*. *J Cell Biol* 164:47-56.
- 1040 61. Charnaud SC, Kumarasingha R, Bullen HE, Crabb BS, Gilson PR. 2018. Knockdown of
1041 the translocon protein EXP2 in *Plasmodium falciparum* reduces growth and protein
1042 export. *PLoS One* 13:e0204785.

- 1043 62. Low LM, Azasi Y, Sherling ES, Garten M, Zimmerberg J, Tsuboi T, Brzostowski J, Mu J,
1044 Blackman MJ, Miller LH. 2019. Deletion of *Plasmodium falciparum* Protein RON3 Affects
1045 the Functional Translocation of Exported Proteins and Glucose Uptake. *MBio* 10.
1046 63. Thomas JA, Tan MSY, Bisson C, Borg A, Umrekar TR, Hackett F, Hale VL, Vizcay-
1047 Barrena G, Fleck RA, Snijders AP, Saibil HR, Blackman MJ. 2018. A protease cascade
1048 regulates release of the human malaria parasite *Plasmodium falciparum* from host red
1049 blood cells. *Nat Microbiol* 3:447-455.
1050 64. Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR,
1051 Blackman MJ, Kursula I, Heussler V, Brochet M, Soldati-Favre D. 2017. A multistage
1052 antimalarial targets the plasmepsins IX and X essential for invasion and egress. *Science*
1053 358:522-528.
1054 65. Elmendorf HG, Haldar K. 1994. *Plasmodium falciparum* exports the Golgi marker
1055 sphingomyelin synthase into a tubovesicular network in the cytoplasm of mature
1056 erythrocytes. *J Cell Biol* 124:449-62.
1057 66. Lauer SA, Rathod PK, Ghori N, Haldar K. 1997. A membrane network for nutrient import
1058 in red cells infected with the malaria parasite. *Science* 276:1122-5.
1059 67. Behari R, Haldar K. 1994. *Plasmodium falciparum*: protein localization along a novel,
1060 lipid-rich tubovesicular membrane network in infected erythrocytes. *Exp Parasitol*
1061 79:250-9.
1062 68. Elford BC, Cowan GM, Ferguson DJ. 1995. Parasite-regulated membrane transport
1063 processes and metabolic control in malaria-infected erythrocytes. *Biochem J* 308 (Pt
1064 2):361-74.
1065 69. Hanssen E, Hawthorne P, Dixon MW, Trenholme KR, McMillan PJ, Spielmann T,
1066 Gardiner DL, Tilley L. 2008. Targeted mutagenesis of the ring-exported protein-1 of
1067 *Plasmodium falciparum* disrupts the architecture of Maurer's cleft organelles. *Mol*
1068 *Microbiol* 69:938-53.
1069 70. Hanssen E, Sougrat R, Frankland S, Deed S, Klonis N, Lippincott-Schwartz J, Tilley L.
1070 2008. Electron tomography of the Maurer's cleft organelles of *Plasmodium falciparum*-
1071 infected erythrocytes reveals novel structural features. *Mol Microbiol* 67:703-18.
1072 71. Hanssen E, Carlton P, Deed S, Klonis N, Sedat J, DeRisi J, Tilley L. 2010. Whole cell
1073 imaging reveals novel modular features of the exomembrane system of the malaria
1074 parasite, *Plasmodium falciparum*. *Int J Parasitol* 40:123-34.
1075 72. Gruring C, Heiber A, Kruse F, Ungefehr J, Gilberger TW, Spielmann T. 2011.
1076 Development and host cell modifications of *Plasmodium falciparum* blood stages in four
1077 dimensions. *Nat Commun* 2:165.
1078 73. Abu Bakar N, Klonis N, Hanssen E, Chan C, Tilley L. 2010. Digestive-vacuole genesis
1079 and endocytic processes in the early intraerythrocytic stages of *Plasmodium falciparum*.
1080 *J Cell Sci* 123:441-50.
1081 74. Jonscher E, Flemming S, Schmitt M, Sabitzki R, Reichard N, Birnbaum J, Bergmann B,
1082 Höhn K, Spielmann T. 2019. PfVPS45 Is Required for Host Cell Cytosol Uptake by
1083 Malaria Blood Stage Parasites. *Cell Host Microbe* 25:166-173.e5.
1084 75. Otto TD, Wilinski D, Assefa S, Keane TM, Sarry LR, Bohme U, Lemieux J, Barrell B,
1085 Pain A, Berriman M, Newbold C, Llinas M. 2010. New insights into the blood-stage
1086 transcriptome of *Plasmodium falciparum* using RNA-Seq. *Mol Microbiol* 76:12-24.
1087 76. Heiber A, Kruse F, Pick C, Gruring C, Flemming S, Oberli A, Schoeler H, Retzlaff S,
1088 Mesen-Ramirez P, Hiss JA, Kadekoppala M, Hecht L, Holder AA, Gilberger TW,
1089 Spielmann T. 2013. Identification of New PNEPs Indicates a Substantial Non-PEXEL
1090 Exportome and Underpins Common Features in *Plasmodium falciparum* Protein Export.
1091 *PLoS Pathog* 9:e1003546.
1092




Figure 1: BiOLD2 identifies the protein contents of the PV/PVM. (A) Schematic showing C-terminal BiOLD2-3xHA fusion to the endogenous *exp2* and *hsp101* genes. (B) Immunofluorescence assay of parental, EXP2-BiOLD2 and HSP101-BiOLD2 parasites grown in media supplemented with 200 μ M biotin. Scale bars are 5 μ m. (C) Western blot of parental, EXP2-BiOLD2 and HSP101-BiOLD2 lines grown in regular RPMI (which contains 820 nM biotin, designated “-”) or 18 hours in RPMI supplemented with 200 μ M biotin (designated “+”). Molecular weights after signal peptide cleavage are predicted to be 61.2 kDa for EXP2-BiOLD2-3xHA and 130 kDa for HSP101-BiOLD2-3xHA. Arrowheads from top to bottom indicate bands expected to correspond to untagged PTEX150 and HSP101. Arrow indicates prominent band at ~23 kDa. (D) Venn diagram summarizing overlapping and distinct proteins detected in EXP2-BiOLD2 and HSP101-BiOLD2 datasets. All proteins identified in untagged negative controls were removed from the BiOLD2 datasets and remaining proteins that were present in both independent replicates of EXP2-BiOLD2 or HSP101-BiOLD2 were used to generate the diagram. (E) Western blot as in (C) probed with anti-EXP1 to show correspondence with prominent ~23 kDa band. Molecular weight after signal peptide cleavage is predicted to be 14.7 kDa for EXP1. Note that EXP1 is observed to migrate at a higher molecular weight than predicted.




Figure 2: Genome editing of the *exp1* locus with Cpf1. (A) Schematic showing strategy for double homologous recombination repair of double-strand breaks mediated by Cas9 or Cpf1 at the 3' end of *exp1*. Individual gRNA target sequences are shown in the zoomed view in the dashed box. Exon sequences are shown in uppercase while intron and UTR sequences are shown in lowercase. 3' UTR, 3' untranslated region; yDHODH, yeast dihydroorotate dehydrogenase; PAM, protospacer adjustment motif. (B) Diagnostic PCR with primers indicated in the schematic and Western blot showing successful integration at the 3' end of *exp1* mediated by either Cas9 or Cpf1. Aldolase serves as a loading control. Molecular weight after signal peptide cleavage is predicted to be 20.9 kDa for EXP1-3xHA-GFP11. Note that EXP1 and derivative fusions are observed to migrate at a higher molecular weight than predicted.




Figure 3: Lethal EXP1 knockdown with a dual aptamer strategy. (A) Schematic of modified *exp1* locus and TDA control of translation in EXP1^{apt} parasites. 2A, *Thosea asigna* virus 2A skip peptide; BSD, blasticidin-S deaminase. (B) Western blot of parental parasite line grown without aTc and EXP1^{apt} parasites grown 48 hours with or without aTc. Aldolase serves as a loading control. Molecular weights after signal peptide cleavage are predicted to be 14.7 kDa for EXP1 and 18 kDa for EXP1-3xHA. Note that EXP1 and derivative fusions are observed to migrate at a higher molecular weight than predicted. Results are representative of three independent experiments. (C) Growth analysis of parental and EXP1^{apt} parasites with or without aTc. Results from one experiment with three technical replicates plotted are shown. The scatter plot shows the slope of the line fitted to the mean of log₂-transformed parasitemias for each of three independent experiments. Error bars indicate SEM. P values were determined by an unpaired, two-sided Student's t-test.




Figure 4: EXP1 *in vivo* function is ablated by a bulky C-terminal fusion but not by mutation of a residue important for GST activity *in vitro*. (A) Schematic showing complementing versions of EXP1 introduced into EXP1^{apt}. (B) Western blot of parent, EXP1^{apt} and complemented lines. Two independently complemented lines were generated with each construct and are designated A or B. Aldolase serves as a loading control. Molecular weights after signal peptide cleavage are predicted to be 18 kDa for EXP1-3xHA, 19.2 kDa for EXP1-WT-3xMYC and EXP1-R70T-3xMYC and 46.2 kDa for EXP1-mNG-3xMYC. Note that EXP1 and derivative fusions are observed to migrate at a higher molecular weight than predicted. (C) Growth analysis of complemented EXP1^{apt} lines with or without aTc. The scatter plot shows the slope of the line fitted to the mean of log₂-transformed parasitemias for four (EXP1-WT-3xMYC), five (EXP1-R70T-3xMYC) or six (EXP1-mNG-3xMYC) independent experiments. Means from independently generated lines complemented with the same version of EXP1 were pooled and are distinguished by different symbols (circles and triangles). Error bars indicate SEM. P values were determined by an unpaired, two-sided Student's t-test. (D) Immunofluorescence assay of EXP1^{apt} complemented lines. Scale bars are 5 μm.




Figure 5: Depletion of EXP1 results in late cycle arrest but does not impact protein export. (A-B) Quantification of parasite stages of development from Giemsa-stained thin smears of (A) EXP1^{apt} and (B) EXP2^{apt} parasites synchronized to a 10-hour window and grown with or without aTc. Time 0 hours indicates the point of aTc removal at which purified late trophozoites (~32-42 hours post-invasion) were mixed with fresh uninfected RBCs. Results from one experiment performed in technical triplicate are shown and are representative of two independent experiments. Error bars indicate SD. Representative images of the majority parasite population at each time point are shown. Scale bars are 2 μ m. (C-D) Immunofluorescence assay showing SBP1, which is exported to the Maurer's clefts, in (C) EXP1^{apt} and (D) EXP2^{apt} parasites. Quantification of SBP1 export beyond the PVM (both EXP1^{apt} and EXP2^{apt} contain a 3xFLAG tag on HSP101 which was used as a marker for the PVM) is shown as MFI of SBP1 within the host compartment or as the number of SBP1-positive puncta (Maurer's clefts) within the host compartment. Merged images of SBP1, FLAG and DAPI signal are shown. The dashed line indicates the boundary of the host RBC traced from the corresponding DIC image. Data are pooled from three independent experiments and n is the number of individual parasite-infected RBCs. Boxes and whiskers delineate 25th-75th and 10th-90th percentiles, respectively. P values were determined by an unpaired, two-sided Student's t-test. MFI, mean fluorescence intensity; AU, arbitrary units. Scale bars are 2 μ m.




Figure 6: Depletion of EXP1 results in PV/PVM morphological abnormalities. (A-E) TEM visualization of parasite ultrastructure in parent and EXP1^{ap} parasites grown 48 hours with or without aTc. Images are shown of (A-D) trophozoites and (E) segmented schizonts. Dashed boxes indicate enlarged areas shown to the right. Arrows indicate PVM and PPM. Arrowheads indicate cytostomes. Double arrowheads indicate abnormal membrane-enclosed structures filled with host cytosol in the PV lumen. Results are representative of two independent experiments. Quantification of morphological abnormalities is shown in Table 2. Scale bars are 500 nm. (F) Live fluorescence imaging of magnet-purified EXP1^{ap}::PV-mRuby3 parasites grown 48 hours with or without aTc. The dashed lines indicate the boundary of infected RBC traced from the corresponding DIC image. Results are representative of three independent experiments. Scale bars are 5 μ m.




Figure 7: Depletion of EXP1 alters EXP2 distribution in the PVM. (A) Western blot of parental parasite line grown without aTc and EXP1^{apt} parasites grown 48 hours with or without aTc. Aldolase serves as a loading control. Molecular weights after signal peptide cleavage are predicted to be 30.8 kDa for EXP2 and 18 kDa for EXP1-3xHA. Note that EXP1 and derivative fusions are observed to migrate at a higher molecular weight than predicted. (B) Live fluorescent images of EXP2-mNG and EXP1^{apt}::EXP2-mNG parasites grown 48 hours with or without aTc. Merged images include EXP2-mNG signal in green together with DIC and BODIPY TR Ceramide signal in red used to trace the PVM. Scale bars are 2 μ m. The corresponding histograms of EXP2-mNG signal along the PVM trace are shown for each cell. Dashed line is the mean of the minimum and maximum EXP2-mNG signal intensity. (C) Quantification of the number of discrete peaks of EXP2-mNG signal exceeding the mean signal threshold as shown in (B) for EXP2-mNG and EXP1^{apt}::EXP2-mNG parasites grown 48 hours with or without aTc. Data are pooled from three independent experiments and *n* is the number of individual parasites. Boxes and whiskers delineate 25th-75th and 10th-90th percentiles, respectively. P values were determined by an unpaired, two-sided Student's t-test. (D) Graph showing the minimum distance along the PVM (given as a percent of total PVM length) containing the indicated amounts of EXP2-mNG fluorescent signal (given as percent of total EXP2-mNG signal per trace) in EXP2-mNG and EXP1^{apt}::EXP2-mNG parasites grown 48 hours with or without aTc. Data points are means from three independent experiments fitted to a smooth line.




Figure S1: Generation of the EXP2-BioID2 fusion line and expression profiles of select hits. (A) Western blot of parent and EXP2-BioID2-3xHA parasites. Molecular weights after signal peptide cleavage are predicted to be 30.8 kDa for EXP2 and 61.2 kDa for EXP2-BioID2-3xHA. (B) Transcript fold change throughout intraerythrocytic development assessed by transcriptomic analysis of synchronized *P. falciparum* 3D7 parasites for EXP2, HSP101, EXP1 and select ETRAMP family members. Data are from RNAseq analysis by Otto and colleagues (75). Genes with similar expression pattern to *exp2* are shown in color. (C) Ven diagram summarizing overlapping and distinct proteins detected in EXP2-BioID2, HSP101-BioID2 and SP-GFP-BirA* datasets (50). Data from Khosh-Naucke et al 2018 was processed in the same way as the BioID2 datasets in this study by pooling SP-GFP-BirA* mass spectrometry datasets obtained from saponin supernatant and pellet fractions and removing all proteins identified in 3D7 negative controls.




Figure S2: Genome editing of *exp1*, *etramp10.2* and *etramp5* with Cpf1. (A) Western blot of parent and EXP1-3xHA-GFP11 fusion parasites generated with AsCpf1 or LbCpf1 and gRNA2 as shown in Figure 2A but expressed from the selectable pUF-AsCpf1 or pUF-LbCpf1 plasmids that contain a yDHODH cassette. Aldolase serves as a loading control. Molecular weight after signal peptide cleavage is predicted to be 20.9 kDa for EXP1-3xHA-GFP11. Note that EXP1 and derivative fusions are observed to migrate at a higher molecular weight than predicted. (B) Schematic showing strategy for double homologous recombination repair of double-strand breaks mediated by Cpf1 at the 3' end of the *etramp10.2* and *etramp5* genes to install a 3xHA fusion and 3' TetR-DOZI-aptamers. 3' UTR, 3' untranslated region; yDHODH, yeast dihydroorotate dehydrogenase. (C,D) Sequence of the 3' end of *etramp10.2* or *etramp5* with Cpf1 gRNA target indicated. Successful integration mediated by AsCpf1 to generate a 3' fusion to 3xHA is shown by diagnostic PCR with primers indicated in the schematic and by Western blot of ETRAMP10.2^{apt} and ETRAMP5^{apt} parasites grown with or without 1 μ M aTc for 96 hours. EXP2 serves as a loading control. Molecular weight after signal peptide cleavage is predicted to be 39.6 kDa for ETRAMP10.2-3xHA and 19.6 kDa for ETRAMP5-3xHA. Similar to EXP1, both ETRAMP10.2-3xHA and ETRAMP5-3xHA are observed to migrate at a higher molecular weight than predicted. PAM, protospacer adjustment motif.




Figure S3: Generation of EXP1^{apt} parasites and analysis of DiCre-mediated *exp1* excision. (A) Schematic for strategy used to replace the endogenous *exp1* coding sequence with a re-coded version of *exp1* with TDA and DiCre elements by Cpf1 editing and double homologous recombination. (B) Diagnostic PCR with primers indicated in the schematic in (A) showing successful integration at the 5' and 3' ends of the *exp1* locus in EXP1^{apt} parasites. The absence of the product in EXP1^{apt} using primers P65/P67 is likely due to the very large amplicon size. (C) Schematic of *exp1* locus following excision between *loxP* sites by DiCre. The pEXP1^{apt} plasmid was designed so that DiCre excision of the modified locus would place the promoter-less *mruby3* coding sequence under the control of the endogenous *exp1* promoter. (D) Growth analysis of parental and EXP1^{apt} parasites with or without 1 μ M aTc or with and without 100 μ M or 250 μ M rapamycin. The scatter plot shows the slope of the line fitted to the mean of log₂-transformed parasitemias for each of three independent experiments. Error bars indicate SEM. (E) Diagnostic PCR for *exp1* excision by DiCre with primers indicated in the schematics.

TABLE 1 Top 30 proteins identified in EXP2-BioID2 and HSP101-BioID2 experiments ranked by NSAF score.

#	EXP2-BioID2_replicate 1		EXP2-BioID2_replicate 2		HSP101-BioID2_replicate 1		HSP101-BioID2_replicate 2	
	Gene ID	Name or localization	Gene ID	Name or localization	Gene ID	Name or localization	Gene ID	Name or localization
1	PF3D7_1471100	EXP2	PF3D7_1436300	PTEX150	PF3D7_1436300	PTEX150	PF3D7_1116800	HSP101
2	PF3D7_1121600	EXP1	PF3D7_1033200	ETRAMP10.2	PF3D7_1116800	HSP101	PF3D7_1436300	PTEX150
3	PF3D7_1436300	PTEX150	PF3D7_1135400	PV Localization (ref 40)	PF3D7_0721100	None	PF3D7_1212000	TPx(GI)
4	PF3D7_1135400	PV Localization (ref 40)	PF3D7_1471100	EXP2	PF3D7_1212000	TPx(GI)	PF3D7_0721100	None
5	PF3D7_1033200	ETRAMP10.2	PF3D7_1024800	EXP3	PF3D7_1033200	ETRAMP10.2	PF3D7_1226900	PV2
6	PF3D7_1335100	MSP7	PF3D7_1212000	TPx(GI)	PF3D7_1135400	PVLocalization (ref 40)	PF3D7_1121600	EXP1
7	PF3D7_1226900	PV2	PF3D7_1129100	PV1	PF3D7_0702500	Exported Protein	PF3D7_1108600	ERC
8	PF3D7_0207500	SERA6	PF3D7_0207500	SERA6	PF3D7_1024800	EXP3	PF3D7_1471100	EXP2
9	PF3D7_1129100	PV1	PF3D7_1335100	MSP7	PF3D7_1121600	EXP1	PF3D7_1135400	PV Localization (ref 40)
10	PF3D7_1212000	TPx(GI)	PF3D7_1226900	PV2	PF3D7_1226900	PV2	PF3D7_0801000	PHISTc
11	PF3D7_0721100	None	PF3D7_1345100	TRX2	PF3D7_1108600	ERC	PF3D7_1033200	ETRAMP10.2
12	PF3D7_1312700	None	PF3D7_1121600	EXP1	PF3D7_1129100	PV1	PF3D7_1129100	PV1
13	PF3D7_1116800	HSP101	PF3D7_0532100	ETRAMP5	PF3D7_0801000	PHISTc	PF3D7_1130100	RPL38
14	PF3D7_1024800	EXP3	PF3D7_1105600	PTEX88	PF3D7_0629200	Partial PV Localization (ref 40)	PF3D7_0702500	Exported Protein
15	PF3D7_1105600	PTEX88	PF3D7_0612700	PTEX88	PF3D7_1130100	RPL38	PF3D7_0625400	None
16	PF3D7_0316300.1	PPase	PF3D7_1116700	DPAP1	PF3D7_1471100	EXP2	PF3D7_1105600	PTEX88
17	PF3D7_1464600	UIS2	PF3D7_0316300.1	PPase	PF3D7_1105600	PTEX88	PF3D7_0202400	PTEF
18	PF3D7_1228600	MSP9	PF3D7_0721100	None	PF3D7_1460700	RPL27	PF3D7_1404900	None
19	PF3D7_0316300.2	PPase	PF3D7_1116800	HSP101	PF3D7_0202400	PTEF	PF3D7_0629200	Partial PV Localization (ref 40)
20	PF3D7_0902800	SERA9	PF3D7_0404900	P41	PF3D7_1104400	Trx-mero	PF3D7_1345100	TRX2
21	PF3D7_1345100	TRX2	PF3D7_1464600	UIS2	PF3D7_1345100	TRX2	PF3D7_1108700	Pfj2
22	PF3D7_1419800	GR	PF3D7_0316300.2	PPase	PF3D7_1404900	None	PF3D7_1335100	MSP7
23	PF3D7_0207800	SERA3	PF3D7_1419800	GR	PF3D7_1108700	Pfj2	PF3D7_1024800	EXP3
24	PF3D7_0532100	ETRAMP5	PF3D7_1334800	MSRP2	PF3D7_0830400	PV/Exported Localization (ref 76)	PF3D7_1008900	AK1
25	PF3D7_1420700	P113	PF3D7_1454400	APP	PF3D7_1016400	FIKK10.1	PF3D7_1232100	CPN60
26	PF3D7_1014100	MSA180	PF3D7_0830400	PV/Exported Localization (ref 76)	PF3D7_1232100	CPN60	PF3D7_0706400	RPL37
27	PF3D7_0207400	SERA7	PF3D7_0902800	SERA9	PF3D7_1008900	AK1	PF3D7_1104400	Trx-mero
28	PF3D7_0702500	Exported	PF3D7_0207800	SERA3	PF3D7_1335100	MSP7	PF3D7_1016400	FIKK10.1
29	PF3D7_0501200	PIESP2	PF3D7_0930300	MSP1	PF3D7_0625400	None	PF3D7_0501200	PIESP2
30	PF3D7_1419800	GR	PF3D7_0207400	SERA7	PF3D7_1001200	ACBP2	PF3D7_1460700	RPL27

Table 2 Quantification of morphological abnormalities in TEM analysis of parent and EXP1^{apt} lines.

Parasite Stage	Morphological Abnormality	Replicate	% of Cells Displaying Abnormality			
			Parent -aTc	EXP1 ^{apt} +aTc	EXP1 ^{apt} -aTc	
Trophozoites	Increased separation between PVM and PPM	1	0	1	8	
		2	2	0	11	
	Increased separation between PVM and PPM with abnormal membrane structures in the PV that contain RBC cytosol	1	0	2	24	
		2	0	0	7	
	TVN-like membrane features in RBC cytosol	1	4	21	26	
		2	11	20	25	
Segmented Schizonts	Increased separation between PVM and PPM	1	0	0	4	
		2	1	0	10	
	Increased separation between PVM and PPM with abnormal membrane structures in the PV that contain RBC cytosol	1	1	3	15	
		2	1	1	15	
	TVN-like membrane features in RBC cytosol	1	2	12	24	
		2	8	8	21	